<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107603</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107603</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107603.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Microbiology and Infectious Disease</subject>
</subj-group>
</article-categories><title-group>
<article-title>An abundant merozoite surface protein of <italic>Plasmodium falciparum</italic> modulates susceptibility to inhibitory antibodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Henshall</surname>
<given-names>Isabelle G</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chmielewski</surname>
<given-names>Jill</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Angage</surname>
<given-names>Dimuthu</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romeo</surname>
<given-names>Ornella</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lai</surname>
<given-names>Keng Heng</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turland</surname>
<given-names>Kaitlin R</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Badii</surname>
<given-names>Nicki</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Foley</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anders</surname>
<given-names>Robin F</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beeson</surname>
<given-names>James</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5073-1405</contrib-id>
<name>
<surname>Wilson</surname>
<given-names>Danny W</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a5">5</xref>
<email>danny.wilson@adelaide.edu.au</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00892tw58</institution-id><institution>Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide</institution></institution-wrap>, <city>Adelaide</city>, <country country="AU">Australia</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01rxfrp27</institution-id><institution>Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Sciences, La Trobe University</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00892tw58</institution-id><institution>Institute for Photonics and Advanced Sensing (IPAS), University of Adelaide</institution></institution-wrap>, <city>Adelaide</city>, <country country="AU">Australia</country></aff>
<aff id="a4"><label>4</label><institution>AdAlta</institution>, <city>Bundoora</city>, <country country="AU">Australia</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ktbsm52</institution-id><institution>Burnet Institute</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>Department of Infectious Diseases, University of Melbourne</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>School of Translational Medicine and Department of Microbiology, Monash University</institution></institution-wrap>, <city>Melbourne</city>, <country country="AU">Australia</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Krzych</surname>
<given-names>Urszula</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Walter Reed Army Institute of Research</institution>
</institution-wrap>
<city>Silver Spring</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Soldati-Favre</surname>
<given-names>Dominique</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Geneva</institution>
</institution-wrap>
<city>Geneva</city>
<country country="CH">Switzerland</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: M.F. is the founding chief scientist and a shareholder in AdAlta Ltd., and R.F.A. is also a shareholder in AdAlta. The other authors have declared no competing interests.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-07-08">
<day>08</day>
<month>07</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107603</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-05-13">
<day>13</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-05-13">
<day>13</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.05.13.653866"/>
</event>
</pub-history>
<permissions>
<copyright-statement>Â© 2025, Henshall et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Henshall et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107603-v1.pdf"/>
<abstract>
<title>Abstract</title><p>Malaria merozoite surface proteins (MSPs), are thought to have important roles in red blood cell (RBC) invasion and their exposure on the parasite surface makes them attractive vaccine candidates. However, their role in invasion has not been directly demonstrated and their biological functions are unknown. One of the most abundant proteins is <italic>Pf</italic>MSP2, which is likely an ancestral protein that has been maintained in the <italic>Plasmodium falciparum</italic> lineage and is a focus of vaccine development, whose function remains unknown. Using CRISPR-Cas9 gene-editing, we removed <italic>Pf</italic>MSP2 from two different <italic>P. falciparum</italic> lines with no impact on parasite replication or phenotype <italic>in vitro</italic>, demonstrating that it is not essential for RBC invasion. However, loss of <italic>Pf</italic>MSP2 led to increased inhibitory potency of antibodies targeting other merozoite proteins involved in invasion, particularly <italic>Pf</italic>AMA1. In a solid-phase model, increasing concentrations of <italic>Pf</italic>MSP2 protein reduced binding of different antibodies against <italic>Pf</italic>AMA1 in a dose dependent manner. These data suggest that <italic>Pf</italic>MSP2 can modulate the susceptibility of merozoites to protective inhibitory antibodies. The results of this study change our understanding of the potential functions of <italic>Pf</italic>MSP2 and establishes a new concept in malaria where a surface protein can reduce the protective efficacy of antibodies targeting a different antigen. These findings have important implications for understanding malaria immunity and informing vaccine development.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>

</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p><italic>Plasmodium falciparum</italic> malaria remains a global health challenge with over half a million deaths annually (<xref ref-type="bibr" rid="c75">World Health Organization, 2024</xref>). Worryingly, increasing parasite resistance to frontline antimalarials and mosquito insecticide resistance are decreasing the effectiveness of key control measures (<xref ref-type="bibr" rid="c75">World Health Organization, 2024</xref>). Development of the RTS,S and R21 vaccines targeting the <italic>P. falciparum</italic> circumsporozoite protein is a step forward for malaria vaccine development, however further improvements in vaccine efficacy and longevity are needed to protect those most at risk â children under 5 years â and enable malaria elimination (<xref ref-type="bibr" rid="c10">Beeson et al., 2019</xref>; <xref ref-type="bibr" rid="c21">Datoo et al., 2024</xref>; <xref ref-type="bibr" rid="c59">RTSS Clinical Trials Partnership, 2015</xref>). Understanding the function of vaccine targets remains important for prioritisation and optimisation of candidates in the development pipeline. Merozoites, the parasite stage that invades host red blood cells (RBCs), have long been targeted for vaccine development since successful blocking of merozoite invasion would prevent the repeated cycles of blood-stage parasite multiplication and associated disease. While much work has been done to understand the processes and steps required for merozoite invasion, only a few merozoite proteins have successfully had functions defined. To date, most vaccines based on merozoite antigens have demonstrated limited efficacy (<xref ref-type="bibr" rid="c9">Beeson et al., 2016</xref>) at least in part due to the extensive polymorphisms exhibited by many of these antigens.</p>
<p>The surface of the merozoite is covered in a fibril coat which is comprised of multiple proteins, broadly known as merozoite surface proteins (MSPs). These proteins have been proposed to mediate weak initial merozoite RBC contact (<xref ref-type="bibr" rid="c7">Bannister et al., 1986</xref>; <xref ref-type="bibr" rid="c9">Beeson et al., 2016</xref>; <xref ref-type="bibr" rid="c18">Cowman et al., 2017</xref>; <xref ref-type="bibr" rid="c72">Weiss et al., 2015</xref>) and in <italic>P. falciparum</italic> are dominated by GPI-anchored proteins, the most abundant being <italic>Pf</italic>MSP1 and 2 (<xref ref-type="bibr" rid="c32">Gilson et al., 2006</xref>). <italic>Pf</italic>MSP1 has been suggested to have a role in merozoite attachment to the RBC (<xref ref-type="bibr" rid="c39">Li et al., 2004</xref>), but recent evidence instead suggests that it has a role in merozoite rupture from schizonts and cellular interaction studies using optical tweezers do not support a substantial role for this protein in RBC binding (<xref ref-type="bibr" rid="c20">Das et al., 2015</xref>; <xref ref-type="bibr" rid="c36">Kals et al., 2024</xref>), although it may have another function in invasion. These recent insights into <italic>Pf</italic>MSP1 function, the best studied MSP, highlight what little is known of MSPs and their roles in parasite survival.</p>
<p><italic>P. falciparum</italic> merozoite surface protein 2 (<italic>Pf</italic>MSP2), a protein proposed to be essential for parasite growth (<xref ref-type="bibr" rid="c62">Sanders et al., 2006</xref>), has been of long-term interest as a vaccine candidate. <italic>Pf</italic>MSP2 is a â¼28 kDa intrinsically disordered protein that has conserved N- and C- termini, along with a central variable region that defines two main allelic groups, 3D7-like and FC27-like (<xref ref-type="bibr" rid="c1">Adda et al., 2012</xref>). While <italic>Pf</italic>MSP2 was theorised to have a mechanical role in the early steps of invasion (<xref ref-type="bibr" rid="c4">Anders et al., 2010</xref>), there is minimal supporting evidence for this, in part due to the lack of tools to study <italic>Pf</italic>MSP2 function. Studies with recombinant proteins suggest that it is likely <italic>Pf</italic>MSP2 interacts with lipids and forms complexes with itself on the merozoite surface (<xref ref-type="bibr" rid="c2">Adda et al., 2009</xref>; <xref ref-type="bibr" rid="c45">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="c78">Zhang et al., 2012</xref>). <italic>Pf</italic>MSP2 peptides have also been reported to bind the RBC and inhibit <italic>P. falciparum</italic> growth, which would support <italic>Pf</italic>MSP2 mediating merozoite-RBC interactions (<xref ref-type="bibr" rid="c49">Ocampo et al., 2003</xref>). Unlike the majority of the merozoite surface coat proteins, <italic>Pf</italic>MSP2 is not present in other malaria parasites that infect humans and has been postulated to have evolved specifically in the <italic>Laverania</italic> subgenus of <italic>Plasmodium</italic>, which includes <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c11">Black et al., 2002</xref>).</p>
<p><italic>Pf</italic>MSP2 has been trialled in a vaccine (Combination B) combined with fragments of <italic>Pf</italic>MSP1 and <italic>Pf</italic>RESA. A Phase 1/2b trial of this vaccine showed efficacy in reducing the parasite burden in children, which was specific to the <italic>Pf</italic>MSP2 3D7-like allele used in the vaccine formulation (<xref ref-type="bibr" rid="c30">Genton et al., 2003</xref>). Vaccine-induced antibodies from clinical trials or experiments in animals have little or no inhibitory activity in standard growth inhibition assays (<xref ref-type="bibr" rid="c14">Boyle et al., 2015</xref>; <xref ref-type="bibr" rid="c48">McCarthy et al., 2011</xref>), but did show functional activity through the recruitment of complement, promoting opsonic phagocytosis and antibody-dependent cellular inhibition (<xref ref-type="bibr" rid="c14">Boyle et al., 2015</xref>; <xref ref-type="bibr" rid="c27">Feng et al., 2018</xref>; <xref ref-type="bibr" rid="c48">McCarthy et al., 2011</xref>). Naturally acquired antibodies are also known to target <italic>Pf</italic>MSP2 and have been linked to protection (<xref ref-type="bibr" rid="c29">Fowkes et al., 2010</xref>; <xref ref-type="bibr" rid="c52">Osier et al., 2010</xref>; <xref ref-type="bibr" rid="c67">Stanisic et al., 2009</xref>; <xref ref-type="bibr" rid="c77">Zerebinski et al., 2024</xref>). Studies have highlighted that it is the Fc-mediated functional activities of these naturally acquired <italic>Pf</italic>MSP2 antibodies, as opposed to direct blocking of <italic>Pf</italic>MSP2 protein function, that correlates best with protection (<xref ref-type="bibr" rid="c14">Boyle et al., 2015</xref>, <xref ref-type="bibr" rid="c13">2014</xref>; <xref ref-type="bibr" rid="c51">Osier et al., 2014</xref>; <xref ref-type="bibr" rid="c56">Reiling et al., 2019</xref>). While <italic>Pf</italic>MSP2 is a key target of naturally acquired malaria immunity, little is known about the function of <italic>Pf</italic>MSP2, hindering its advancement as a potential vaccine candidate.</p>
<p>Here we take a reverse genetics approach to assess the function of <italic>Pf</italic>MSP2, quantifying the impacts of <italic>Pf</italic>MSP2 deletion on parasite invasion and phenotype. Given our findings that deletion of MSP2 did not impact invasion <italic>in vitro</italic>, we tested the alternative hypothesis that merozoite surface proteins may function to modulate susceptibility of merozoites to inhibitory antibodies.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Avian malaria MSP2-like proteins are structurally similar to <italic>Laverania</italic> MSP2s and show that MSP2 did not arise exclusively in this clade</title>
<p>Genome annotations of <italic>pfmsp2</italic> show it lies between the merozoite surface protein <italic>pfmsp5</italic> (PF3D7_0206900) and <italic>pfmsp</italic>4 (PF3D7_0207000), and the conversed purine biosynthesis enzyme <italic>adenylosuccinate lyase</italic> (ADSL, PF3D7_0206700) (<xref rid="fig1" ref-type="fig">Figure 1A</xref>) (PlasmoDB; (<xref ref-type="bibr" rid="c6">Aurrecoechea et al., 2009</xref>)), with this arrangement previously thought to be restricted to the <italic>Laverania</italic> clade which includes parasites that infect great apes and <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c11">Black et al., 2002</xref>; <xref ref-type="bibr" rid="c28">Ferreira et al., 2015</xref>). As described by <xref ref-type="bibr" rid="c26">Escalante et al. (2022)</xref>, we found the genomes of the two annotated avian <italic>Plasmodium</italic> spp. available on PlasmoDB, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic>, to also have a putative gene between ADSL and MSP5 with structural similarities to <italic>Laverania</italic> MSP2s. The reduced length of the <italic>P. relictum</italic> (PRELSG_0415300) and <italic>P. gallinaceum</italic> (PGAL8A_00017700) MSP2-like proteins compared to those of <italic>Laverania</italic> parasites is accounted for by the absence of any extended central domains of the two avian malaria parasites (<xref ref-type="fig" rid="figs1">Supplementary Figure 1</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Presence and structure of MSP2 across different <italic>Plasmodium</italic> species.</title>
<p><bold>(A)</bold> Schematic of the gene arrangement surrounding <italic>msp2</italic> on <italic>P. falciparum</italic> chromosome 2. <bold>(B)</bold> AlphaFold2 structural predictions of example <italic>Laverania</italic> (<italic>P. falciparum</italic> (3D7), <italic>P. reichenowi</italic>, <italic>P. billcollinsi</italic>, <italic>P. adleri</italic>) and the two avian (<italic>P. relictum</italic>, <italic>P. gallinaceum</italic>) malaria species. The N-terminal signal peptide and C-terminal GPI anchor sequences were removed before the proteins structure was predicted. The most N-terminal amino acid is indicated. Colours represent the predicted local distance difference test (pLDDT) scores, with dark blue representing very high confidence (&gt;90%), light blue high confidence (90 to &gt;70), yellow low confidence (70 to 50) and orange very low confidence (&lt;50). the Modelled structure of the N-terminal helical region is provided as an inset for <italic>P. falciparum</italic> 3D7 MSP2 in isolation, and also in alignment with the helical domain for <italic>P. falciparum</italic> 3D7 (green for all) for the other examples of <italic>Laverania</italic> and avian MSPs (other colours). <bold>(C)</bold> Maximum likelihood tree showing relationship of MSP2 protein sequences found in different <italic>P. falciparum</italic> isolates and other <italic>Plasmodium</italic> species. Grouping of sequences from <italic>P. falciparum</italic> isolates into two main allele types can be seen as well as the separation of the <italic>Laverania</italic> and avian malaria species into their expected groups. Tree robustness tested by bootstrap.</p></caption>
<graphic xlink:href="653866v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>It is estimated that â¼10 million years of evolution separate the avian malaria parasites <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> from the <italic>Laverania</italic> (<xref ref-type="bibr" rid="c12">BÃ¶hme et al., 2018</xref>). Therefore, we explored whether similarities in amino acid sequence and predicted conformation would support a shared lineage and functional properties of MSP2 between <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2s with <italic>Laverania</italic> MSP2 sequences. The primary translation product of <italic>Pf</italic>MSP2 has hydrophobic N- and C-terminal sequences that correspond to secretion signals (SP) and GPI-attachment signals, respectively, which are absent from the mature polypeptide on the merozoite surface. The putative SP (<xref ref-type="fig" rid="figs1">Supplementary Figure 1</xref>, <xref rid="tbl1" ref-type="table">Table 1</xref>) has an amino acid similarity (BLSM62) of &gt;89% across the <italic>Laverania</italic> and avian malaria parasites, whereas, the C-terminal GPI signal sequences of â¼24 residues shows &gt;79% amino acid similarity and shared hydrophobicity across the <italic>Laverania</italic> and avian malarias. Both <italic>P. relictum</italic> (Asp, Ala, Ser: based on big-PI Predictor (<xref ref-type="bibr" rid="c25">Eisenhaber et al., 1999</xref>)) and <italic>P. gallinaceum</italic> (Asp, Gly Ala) MSP2s have a sequence of three amino acids with short side chains immediately prior to this C-terminal hydrophobic region which, although different to the conserved sequence seen with the <italic>Laverania</italic> (Ser, Asn, Ile/Met (<xref ref-type="bibr" rid="c65">Smythe et al., 1991</xref>)), conforms to an amino acid sequence expected for a GPI signal (<xref ref-type="bibr" rid="c32">Gilson et al., 2006</xref>) (<xref ref-type="fig" rid="figs1">Supplementary Figure 1</xref>). Typically, N-terminal of a GPI cleavage site lies an unstructured linker region of up to 10 amino acids rich in polar residues, as seen for <italic>Laverania</italic> MSP2s (polar residues: 50% 2 species to 70% 4 species). For the <italic>Laverania</italic>, this region has almost no Acidic amino acids (Acidic residues: 0% 7 species to 10% 3 species) (<xref ref-type="fig" rid="figs1">Supplementary Figure 1</xref>, <xref rid="tbl1" ref-type="table">Table 1</xref>). In contrast, this region has reduced levels of polar, but is enriched in acidic amino acids, for both <italic>P. relictum</italic> (20% polar, 40% acidic) and <italic>P. gallinaceum</italic> (10% polar, 30% acidic). Although there are some differences in the N and C-terminal regions between <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> and the <italic>Laverania</italic> MSP2s, these signal sequences are broadly conserved in properties which suggests a conserved sub-cellular localisation.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Amino acids sequence properties for the N and C-terminal conserved, and N-terminal repeat, regions for available <italic>P. falciparum</italic> 3D7, <italic>Laverania</italic> (including 3 <italic>Laverania</italic> sequences of unknown speciation) <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2 sequences.</title></caption>
<graphic xlink:href="653866v1_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<p>Immediately downstream of the N-terminal SP lies the 24 amino acid N-terminal conserved region (<xref ref-type="fig" rid="figs2">Supplementary Figure 2</xref>). This region of MSP2 has a propensity for alpha-helical structure and fibril formation (<xref ref-type="bibr" rid="c76">Yang et al., 2010</xref>). Amino acid similarity through the N-terminal conserved region is 78% across the <italic>Laverania</italic> and avian parasites, resulting in similar proportions of hydrophobic, polar uncharged, basic and acidic amino acid across this region (<xref rid="tbl1" ref-type="table">Table 1</xref>). Following the N-terminal conserved regions lies the dimorphic central variable repeat region in <italic>P. falciparum</italic> MSP2s that are grouped as 3D7 or FC27-like amino acid sequence structures. A defining feature of the 3D7-like MSP2 family are 4 or 8-mer tandem repeats consisting of small amino acids (for 3D7: Gly, Gly, Ser, Ala) (<xref ref-type="bibr" rid="c47">MacRaild et al., 2015</xref>; <xref ref-type="bibr" rid="c65">Smythe et al., 1991</xref>). The FC27-like MSP2 family also has repeats of 12 or 32 amino acids in length, but these do not resemble those of the 3D7-like family. We found that the non-<italic>P. falciparum Laverania</italic> and avian malaria MSP2 sequences compared consisted of &gt;75% small amino acids (some of: Gly, Ser, Ala, Thr) generally ordered in repeats downstream of the N- terminal conserved region (<xref ref-type="fig" rid="figs3">Supplementary Figure 3</xref>). The number of repeats (4-repeats = 5 examples to 8 repeats = <italic>P. relictum</italic>), the length of the repeats (3-amino acids = 5 examples to 7-amino acids = <italic>P. praefalciparum</italic>) and whether the repeats were highly conserved or had various levels of degeneracy (conserved = 4 examples to partially or highly degenerate = 10 examples) differed between and within species (<xref rid="tbl1" ref-type="table">Table 1</xref>, Supplementary Figure 3). A broader search of an additional nine <italic>Laverania</italic> MSP2s identified from the NCBI experimental database did not reveal any repeat or central variable regions that resembled FC27-like MSP2s (data not shown). This comparison highlights the surprising finding that a region of known dimorphic variability in <italic>P. falciparum</italic> MSP2 is likely to retain functional constraints that favour small amino acid rich repeats immediately downstream of the N-terminal conserved region. Broadly speaking, this groups the compared <italic>Laverania</italic> and avian malaria MSP2s as having a 3D7-like repeat structure.</p>
<p>Upstream of the C-terminal GPI signal sequence lies the 50 amino acid residue C-terminal conserved region (<xref ref-type="fig" rid="figs4">Supplementary Figure 4</xref>). This region contains two cysteine residues in all <italic>Laverania</italic> MSP2s, which are thought to form an intramolecular disulphide bond (<xref ref-type="bibr" rid="c79">Zhang et al., 2008</xref>). Two cysteine residues are present in the C-terminus of <italic>P. gallinaceum</italic>, but not <italic>P. relictum</italic> MSP2 which has a single cysteine (<xref ref-type="fig" rid="figs4">Supplementary Figure 4</xref>). <italic>Laverania</italic> MSP2 similarity through the 50 residue sequence that makes up the C-terminal conserved region was 80%, with the hydrophobic residues making up between 20% (<italic>P. billcollinsi</italic>) and 34% (<italic>P. adleri</italic>) of the amino acid content (<xref rid="tbl1" ref-type="table">Table 1</xref>). Amino acid similarity dropped to 62% when all available C-terminal conserved domain residues were compared between <italic>Laverania</italic> and the avian malarias due to the limited amino acid sequence similarity upstream of the cysteine residue/s and apparent insertions of 20 (<italic>P. relictum</italic>) and 26 (<italic>P. gallinaceum</italic>) amino acids downstream of the first Cysteine (<xref ref-type="fig" rid="figs4">Supplementary Figure 4</xref>). However, the percentage of hydrophobic residues for <italic>P. relictum</italic> (33%) and <italic>P. gallinaceum</italic> (34%) was broadly in line with that seen for the <italic>Laverania</italic>.</p>
<p>Extensive studies on recombinant proteins of the <italic>P. falciparum</italic> 3D7 and FC27 variants of <italic>Pf</italic>MSP2 have shown this merozoite surface protein to be intrinsically disordered. Given the evidence for conservation of the primary structure of MSP2s from distantly related malaria parasites, we used AlphaFold2 predictions (<xref ref-type="bibr" rid="c35">Jumper et al., 2021</xref>) to examine whether there were likely to be also conformational similarities between <italic>Laverania</italic> MSP2s and those of <italic>P. relictum</italic> and <italic>P. gallinaceum</italic>. The MSP2s in the database of AlphaFold2-predicted structures retain their N- and C-terminal signal sequences, but as these are both absent from mature MSP2 on the merozoite surface they were deleted from the MSP2 sequences used for the AlphaFold2 predictions reported here. The predicted structures of the two avian parasite MSP2s, and other <italic>Laverania</italic> MSP2s, are very similar to that of <italic>Pf</italic>3D7 MSP2, with most of the polypetide chains lacking predicted secondary structure and, from the colour coding, have a predicted local distance test (pLDDT) consistent with that of an intrinsically disordered protein over the majority of the proteins length (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). In contrast to the rest of the polypeptide, some Î±-helical structure was predicted in the conserved 20-residue N-terminal region of all the <italic>Laverania</italic> and avian MSP2s. NMR studies with recombinant <italic>Pf</italic>3D7 and <italic>Pf</italic>FC27 MSP2 showed this conserved N-terminal sequence to have a propensity for forming an Î±-helix that was stabilized in the presence of lipid mimetics (<xref ref-type="bibr" rid="c46">MacRaild et al., 2012</xref>). The low pLDDT values are consistent with this region in the other <italic>Laverania</italic> and <italic>P. gallinaceum</italic> MSP2 having some propensity for Î±-helix formation, whereas higher pLDDT values suggest the possible presence of a more stable Î±-helix in this region of <italic>P. relictum</italic> MSP2.</p>
<p>Having established that MSP2 is present across different <italic>Plasmodium</italic> lineages sharing similar predicted amino acid compositions and structural features, the phylogenetic relationship between annotated <italic>Laverania</italic> and putative avian malaria parasite MSP2s was examined. A phylogenetic tree was generated based on alignments of representative sequences from each species. MSP2 sequences from species belonging to the <italic>Laverania</italic> subgenus all grouped together with two smaller clusters, corresponding to the known <italic>Laverania</italic> clade A and clade B species (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). As expected, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2 also group together. The phylogenetic tree generated based on MSP2 sequences mirrors the proposed evolution of <italic>Plasmodium</italic> spp. (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). As postulated by <xref ref-type="bibr" rid="c26">Escalante et al. (2022)</xref>, these data suggest that MSP2 was likely present in the ancestral <italic>Plasmodium</italic> parasite prior to the split of the mammalian infecting <italic>Plasmodium</italic> spp. from those that infect birds and lizards. Given the shared amino acid sequence and predicted conformational similarities, including the high levels of intrinsically disordered sequence outside of the N- and C-terminal regions, the <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2-like proteins appear likely to contain enough properties to potentially be functionally equivalent to <italic>Laverania</italic> MSP2s. This conservation of MSP2-like proteins across different species suggests it has an important function.</p>
</sec>
<sec id="s2b">
<title>Loss of <italic>Pf</italic>MSP2 does not noticeably impact growth or invasion of different <italic>P. falciparum</italic> lines <italic>in vitro</italic></title>
<p>Given previous unsuccessful attempts to disrupt <italic>pfmsp2</italic> (<xref ref-type="bibr" rid="c62">Sanders et al., 2006</xref>), and its high abundance on the merozoite surface (<xref ref-type="bibr" rid="c32">Gilson et al., 2006</xref>), <italic>Pf</italic>MSP2 has been traditionally viewed as an essential <italic>P. falciparum</italic> protein with an essential function in merozoite invasion. We employed CRISPR-Cas9 gene editing to determine whether the reported inability to knock-out <italic>pfmsp2 in vitro</italic> was a result of this protein being essential for parasite survival or because of the lower efficiency of the previously used gene-editing system (<xref ref-type="bibr" rid="c62">Sanders et al., 2006</xref>). Unexpectedly, we confirmed successful disruption of <italic>pfmsp2</italic> by replacing the coding sequence between 132 bp and 819 bp of the gene with a hDHFR drug selection cassette in the 3D7 <italic>P. falciparum</italic> laboratory-adapted line (<xref rid="fig2" ref-type="fig">Figure 2A</xref> and <xref rid="fig2" ref-type="fig">B</xref>), resulting in <italic>Pf</italic>3D7 ÎMSP2 parasites. We confirmed that <italic>Pf</italic>MSP2 was no longer expressed in <italic>Pf</italic>3D7 ÎMSP2 parasites by western blot, which detected a MSP2 band around 50 kDa in <italic>Pf</italic>3D7 WT parasite material but not in <italic>Pf</italic>3D7 ÎMSP2 parasites (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Similarly, immunofluorescence microscopy using anti- <italic>Pf</italic>MSP2 rabbit polyclonal antibodies showed the expected surface localisation of MSP2 on <italic>Pf</italic>3D7 WT merozoites but not on <italic>Pf</italic>3D7 ÎMSP2 parasites (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). We next assessed whether knock-out of <italic>Pf</italic>MSP2 impacted on parasite growth over one or two cycles of development <italic>in vitro</italic> and found that deletion of <italic>Pf</italic>3D7 MSP2 did not cause any significant change in growth (<xref rid="fig2" ref-type="fig">Figure 2E</xref> and <xref rid="fig2" ref-type="fig">F</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title><italic>Pf</italic>MSP2 is not essential for growth <italic>in vitro</italic> of <italic>Pf</italic>3D7 blood stage parasites.</title>
<p><bold>(A-B)</bold> Schematic and agarose gel showing integration of knockout construct (band A+C) in the <italic>msp2</italic> gene locus and absence of the <italic>msp2</italic> sequence from the <italic>Pf</italic>3D7 ÎMSP2 line (band A+B). Western Blot of late schizont protein extracts confirms no <italic>Pf</italic>MSP2 is expressed in the <italic>Pf</italic>3D7 ÎMSP2 line. <italic>Pf</italic>MSP2 detected by anti-<italic>Pf</italic>MSP2 2F2 3D7 mAb with <italic>Pf</italic>Aldolase serving as loading control. Representative image shown. <bold>(D)</bold> Distribution of key merozoite surface proteins in the presence or absence of <italic>Pf</italic>MSP2 was visualised by immunofluorescence. <italic>Pf</italic>MSP2 (red for top two rows, purple in bottom two rows), the nucleus stained by DAPI (blue in merge) and <italic>Pf</italic>AMA1 (purple, top two rows) or <italic>Pf</italic>MSP1 19 (red, bottom two rows), and the coloured merge of the proceeding panels. Scale bar = 0.7 Âµm. Representative images shown from a minimum of 10 schizonts imaged per condition. <bold>(E-F)</bold> Growth of <italic>Pf</italic>3D7 WT compared to <italic>Pf</italic>3D7 ÎMSP2 <italic>P. falciparum</italic> parasites, measured as fold increase in parasitaemia, over one (48 hrs) or two (96 hrs) cycles in either standard (still- (E)) or shaking (F) conditions. Parasitaemia was determined by flow cytometry at the start and end to calculate fold increase. Graph displays mean Â± S.D. of three independent experiments performed with technical triplicates. Significance determined by unpaired t-test with p&lt; 0.05 deemed significant.</p></caption>
<graphic xlink:href="653866v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>As <italic>Pf</italic>MSP2 has been considered, to this point, as essential for <italic>P. falciparum</italic> growth <italic>in vitro</italic> (<xref ref-type="bibr" rid="c62">Sanders et al., 2006</xref>), we investigated whether <italic>Pf</italic>MSP2 could also be removed from <italic>Pf</italic>Dd2, an isolate of <italic>P. falciparum</italic> that differs from 3D7 in geographical origin, RBC receptor usage and allelic type of <italic>pfmsp2</italic>. Using CRISPR-Cas9 we successfully knocked-out <italic>msp2</italic> in <italic>Pf</italic>Dd2 (<xref rid="fig3" ref-type="fig">Figure 3</xref> A and B) and confirmed the absence of the protein in <italic>Pf</italic>Dd2 ÎMSP2 parasites using western blot (<xref rid="fig3" ref-type="fig">Figure 3C</xref>). As we found for <italic>Pf</italic>3D7, deletion of <italic>Pf</italic>Dd2 <italic>msp2</italic> did not result in a significant impact on parasite growth over one or two cycles of parasite replication (<xref rid="fig3" ref-type="fig">Figure 3D</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title><italic>Pf</italic>Dd2 does not require MSP2 for asexual growth <italic>in vitro</italic>.</title>
<p><bold>(A-B)</bold> Successful integration of KO construct (schematic in A) into the <italic>msp2</italic> gene locus of <italic>Pf</italic>Dd2 ÎMSP2 was confirmed by PCR of genomic DNA (primers A+B amplify WT locus, primers D+E amplify integrated KO construct). <bold>(C)</bold> Loss of <italic>Pf</italic>MSP2 expression was demonstrated by western blot of schizont protein extract with <italic>Pf</italic>MSP2 detected by anti-<italic>Pf</italic>MSP2 FC27 and anti-<italic>Pf</italic>EXP2 as loading control. Representative image shown. <bold>(D)</bold> Growth of <italic>Pf</italic>Dd2 WT <italic>P. falciparum</italic> parasites and <italic>Pf</italic>Dd2 ÎMSP2 over one (48 hrs) or two (96 hrs) cycles. Parasitaemia was determined by flow cytometry at the start and end to calculate fold increase. Graph displays mean Â± S.D. of three independent experiments performed with technical triplicates. <bold>(E-H)</bold> Key parameters of merozoite invasion were measured for both <italic>Pf</italic>Dd2 WT and <italic>Pf</italic>Dd2 ÎMSP2 parasites that had successfully invaded a RBC using live cell imaging of merozoite invasion. Time to merozoite attachment to RBCs <bold>(E)</bold>, length <bold>(F)</bold> and strength <bold>(G)</bold> of RBC deformation, and time to complete merozoite invasion <bold>(H)</bold> were measured by live microscopy. A minimum of 30 invading merozoites for each line were captured and assessed. Significance determined by unpaired t-test with p&lt; 0.05 deemed significant.</p></caption>
<graphic xlink:href="653866v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Given the abundance of <italic>Pf</italic>MSP2 on the merozoite surface, we postulated that loss of this protein may impact on the timing of merozoite invasion of the RBC, which is not reflected in reduced growth in <italic>in vitro</italic> cultures. Previous studies using live-cell microscopy have reported that merozoites first contact the RBC and form weak initial interactions. The merozoite then reorientates to bring apical organelles into position to release their contents onto the RBC, which then leads to formation of the tight junction, merozoite invasion through the tight-junction, formation of the parasitophorous vacuole and resealing of the RBC membrane post-entry (<xref ref-type="bibr" rid="c72">Weiss et al., 2015</xref>). Given its surface localization, <italic>Pf</italic>MSP2 has been speculated to act in the early phase of merozoite attachment. To assess whether knock-out of <italic>pfmsp2</italic> impacted on the progression of invasion, we used live-cell microscopy of <italic>Pf</italic>Dd2 ÎMSP2 parasites and compared the timing and key steps of invasion to <italic>Pf</italic>Dd2 WT parasites <italic>in vitro</italic>. This analysis showed that <italic>Pf</italic>Dd2 ÎMSP2 knock-out parasites had no detectable alteration in the time the parasite takes to attach to the RBC, the length or strength of RBC deformation as the merozoite begins entry or for the time it took for invasion to be completed compared to <italic>Pf</italic>Dd2 WT (<xref rid="fig3" ref-type="fig">Figure 3 E-H</xref>). Together these data show <italic>Pf</italic>MSP2 is not essential for blood-stage replication <italic>in vitro</italic> in two <italic>P. falciparum</italic> laboratory isolates from different geographical regions and knock-out of <italic>Pf</italic>MSP2 does not seem to impact parasite growth or merozoite invasion <italic>in vitro</italic>. However, its conservation across diverse <italic>Plasmodium</italic> spp. suggests it does play an important function or is advantageous for parasite survival.</p>
</sec>
<sec id="s2c">
<title>Impact of MSP2 gene deletion on gene expression and invasion pathway usage</title>
<p>Because of the close proximity of the <italic>pfmsp</italic>2, 4 and 5 genes on chromosome 2, similarities in their structure (e.g. GPI-anchor intrinsically disordered protein) and shared merozoite surface localization, we used qPCR to assess whether knock-out of <italic>Pf</italic>3D7 MSP2 impacted the expression levels of <italic>Pf</italic>3D7 MSP4 or MSP5. We found no change in MSP4 and MSP5 expression levels between <italic>Pf</italic>3D7 ÎMSP2 parasites and <italic>Pf</italic>3D7 WT parasites (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). As expected, <italic>Pf</italic>MSP2 was not detected in the <italic>Pf</italic>3D7 ÎMSP2 parasites.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>The impact of the loss of <italic>Pf</italic>MSP2 on expression of known merozoite invasion genes and invasion pathway utilization.</title>
<p><bold>(A)</bold> Impact of <italic>Pf</italic>MSP2 KO on transcription during schizonts was assessed by qPCR for genes located in proximity to <italic>Pfmsp</italic>2 on chromosome 2. Changes in expression between <italic>Pf</italic>3D7 WT and <italic>Pf</italic>3D7 ÎMSP2 parasites was determined by qPCR relative to <italic>pfaldolase</italic> expression with <italic>pfsub1</italic> serving as a schizont stage control. Graph displays mean Â± S.D. of three independent RNA harvests. <bold>(B)</bold> Selective enzymatic cleavage of key RBC receptors showed no difference in invasion preference between <italic>Pf</italic>3D7MSP2 WT and <italic>Pf</italic>3D7 ÎMSP2 parasites. Parasitaemia was determined by flow cytometry and compared to growth in non-treated control RBCs. Graph displays mean Â± S.D. of three independent experiments. <bold>(C)</bold> Log2(fold change) for differentially expressed genes, including multigene families, between the transcriptome of <italic>Pf</italic>3D7 WT and <italic>Pf</italic>3D7 ÎMSP2 schizonts. Black lines differentiate genes with a log2 (fold change) &gt; 0.5 and &lt; â0.5 with adjusted p-value &lt; 0.05. Four independent schizont RNA harvests were performed and analysed. Significance determined by t-test with p&lt; 0.05 deemed significant.</p></caption>
<graphic xlink:href="653866v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Secreted <italic>P. falciparum</italic> antigens belonging to the erythrocyte binding antigen (EBA) and reticulocyte binding homologue (Rh) families are known to facilitate host-cell invasion through specific receptors on the RBC surface. Reliance on specific EBA or Rh proteins, or their cognate host-cell receptor, define different invasion pathways that can be crudely described by the sensitivity of merozoite invasion to cleavage of RBC surface proteins with trypsin, chymotrypsin and neuraminidase (<xref ref-type="bibr" rid="c8">Baum et al., 2005</xref>; <xref ref-type="bibr" rid="c24">Duraisingh et al., 2003</xref>; <xref ref-type="bibr" rid="c50">Orlandi et al., 1992</xref>).When we assessed whether <italic>Pf</italic>MSP2 knock-out impacted merozoite invasion pathway usage, we found that <italic>Pf</italic>3D7 ÎMSP2 parasites grew equally as well as <italic>Pf</italic>3D7 WT parasites in all enzyme-treated RBCs (<xref rid="fig4" ref-type="fig">Figure 4B</xref>).</p>
<p>To investigate whether <italic>Pf</italic>MSP2 knock-out caused any changes in gene-expression of proteins that may have a role in merozoite invasion and possibly compensate for loss of <italic>Pf</italic>MSP2, we undertook RNA sequencing and differential gene expression analysis of <italic>Pf</italic>3D7 ÎMSP2 and <italic>Pf</italic>3D7 WT parasites. As expected, the <italic>Pf</italic>MSP2 transcript, which was targeted for removal by our CRISPR-Cas9 strategy, was not detected in the <italic>Pf</italic>3D7 ÎMSP2 parasites between 132 bp and 819 bp (<xref ref-type="fig" rid="figs5">Supplementary Figure 5</xref>). After removal of genes belonging to variant surface antigen families from the data, eight proteins were found to have a log2fold expression increase above 1; none of these proteins are annotated as a merozoite surface or secreted protein linked to merozoite invasion (<xref rid="fig4" ref-type="fig">Figure 4C</xref>, <xref rid="tbl2" ref-type="table">Table 2</xref>). Five of these eight upregulated proteins are of unknown function and expressed at schizont stages, and only one (<italic>Pf</italic>3D7_0909100) has a transmembrane domain that could possibly anchor it to a membrane surface as the GPI anchor does for <italic>Pf</italic>MSP2 (<xref rid="tbl2" ref-type="table">Table 2</xref>). Three proteins were found to have a log2fold expression of &lt;-1, indicating a significant reduction in expression with <italic>Pf</italic>MSP2 knock-out, with <italic>Pf</italic>MSP2 being one of these and the other two predicted to be exported proteins (<xref rid="fig4" ref-type="fig">Figure 4C</xref>, <xref rid="tbl2" ref-type="table">Table 2</xref>). While these data do not exclude any of the <italic>Plasmodium</italic> proteins with unknown function that are upregulated in <italic>Pf</italic>3D7 ÎMSP2 parasites as having a role that compensates for the loss of <italic>Pf</italic>MSP2, only one is predicted to have a transmembrane domain that would bind it to a membrane and no protein identified as up or down-regulated with <italic>Pf</italic>MSP2 knock-out has previously been linked to merozoite invasion. Therefore, <italic>Pf</italic>MSP2 knock-out does appear to have led to changes in gene expression, but does not appear to have a significant impact on the regulation of known merozoite surface or secreted protein gene-expression that would suggest loss of <italic>Pf</italic>MSP2 is compensated for by another protein.</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><title>Genes significantly up or down-regulated with Pf3D7 MSP2 KO</title></caption>
<graphic xlink:href="653866v1_tbl2.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s2d">
<title>Impact of <italic>Pf</italic>MSP2 disruption on antibodies and inhibitors targeting secreted surface exposed antigens</title>
<p>Merozoites are key targets of antibodies during malaria infection with antibodies either able to directly block protein function and thus merozoite invasion, or recruit effectors such as complement leading to the destruction of the merozoite (<xref ref-type="bibr" rid="c9">Beeson et al., 2016</xref>). Given the prominence of <italic>Pf</italic>MSP2 on the merozoite surface we asked the question; how does the loss of <italic>Pf</italic>MSP2 affect antibody efficacy against merozoites?</p>
<p><italic>Pf</italic>EBAs and <italic>Pf</italic>Rhs moderate early steps in invasion with a degree of redundancy between these proteins. Several EBAs and Rhs can be targeted with invasion inhibitory antibodies and are targets of acquired human antibodies (<xref ref-type="bibr" rid="c54">Persson et al., 2013</xref>, <xref ref-type="bibr" rid="c55">2008</xref>; <xref ref-type="bibr" rid="c58">Richards et al., 2013</xref>). We found no significant difference in the ability of purified rabbit immunoglobulin raised against single (<italic>Pf</italic>Rh2b) or combinations of <italic>Pf</italic>EBAs and <italic>Pf</italic>Rhs (<italic>Pf</italic>EBA175/<italic>Pf</italic>Rh2b, <italic>Pf</italic>EBA175/<italic>Pf</italic>Rh4, <italic>Pf</italic>EBA175/<italic>Pf</italic>Rh2b/<italic>Pf</italic>Rh4) to inhibit growth of <italic>Pf</italic>3D7 WT or <italic>Pf</italic>3D7 ÎMSP2 parasites (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Similarly, knock-out of MSP2 in <italic>Pf</italic>Dd2 did not significantly change the parasites sensitivity to rabbit antibodies raised against isogeneic W2mef EBA175 (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Broadly speaking, these results mirror what was seen with selective cleavage of the RBC ligands of <italic>Pf</italic>EBAs and <italic>Pf</italic>Rhs using enzyme treatment of RBCs (<xref rid="fig4" ref-type="fig">Figure 4B</xref>), with no evidence that loss of <italic>Pf</italic>MSP2 changed either the importance of these secreted merozoite antigens during invasion or their sensitivity to antibodies targeting different antigens.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Impact of <italic>Pf</italic>MSP2 removal on efficacy of antibodies targeting other merozoite surface-exposed antigens.</title>
<p>Changes in antibody efficacy in the absence of <italic>Pf</italic>MSP2 was assessed by measuring changes in antibody invasion inhibition and subsequent growth compared to growth in the absence of antibody for both <italic>P. falciparum</italic> WT and ÎMSP2 parasites over 2 cycles. <bold>(A)</bold> Rabbit (Rb) IgG raised against merozoite antigens of the <italic>Pf</italic>3D7 EBA/Rh family. <bold>(B)</bold> Rabbit sera raised against <italic>Pf</italic>Dd2 EBA175. <bold>(C)</bold> Rabbit IgG raised against <italic>Pf</italic>3D7 Rh5. <bold>(D)</bold> Nanobody (nAb) to <italic>Pf</italic>3D7 PTRAMP. <bold>(E-F)</bold> Nanobody and Fc-tagged nanobody to <italic>Pf</italic>3D7 CSS. <bold>(G)</bold> The invasion inhibitory glycosaminoglycan heparin. <bold>(H)</bold> Rabbit sera raised against <italic>Pf</italic>3D7 MSP1-19 (different vaccinated rabbit sera identified by numbers). Graph displays mean Â± S.D. of three different experiments. Significance was determined by unpaired t-test when only a single concentration point was tested and for IC<sub>50</sub> comparisons an extra Sum-of-Squares F Test (best-fit LogIC<sub>50</sub>) was performed with p&lt; 0.05 deemed significant.</p></caption>
<graphic xlink:href="653866v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The interaction of <italic>Pf</italic>Rh5 with RBC surface receptor basigin is a critical, non-redundant interaction for <italic>P. falciparum</italic> merozoite invasion and a known target of direct invasion-inhibitory antibodies (<xref ref-type="bibr" rid="c3">Alanine et al., 2019</xref>; <xref ref-type="bibr" rid="c19">Crosnier et al., 2011</xref>; <xref ref-type="bibr" rid="c23">Douglas et al., 2011</xref>). <italic>Pf</italic>Rh5 was the initial member of the PCRCR complex to be described, with subsequent studies demonstrating that antibodies against other members of this complex could also block merozoite invasion of the RBC (<xref ref-type="bibr" rid="c63">Scally et al., 2022</xref>). Given the importance of these secreted antigens to current vaccine development efforts, we next investigated whether loss of <italic>Pf</italic>MSP2 impacted on the parasiteâs sensitivity to antibodies targeting these antigens. There was no difference in sensitivity between <italic>Pf</italic>3D7 WT and <italic>Pf</italic>3D7 ÎMSP2 parasites when treated with invasion-inhibitory rabbit antibodies targeting <italic>Pf</italic>Rh5 (<xref rid="fig5" ref-type="fig">Figure 5C</xref>) or nanobodies targeting PCRCR complex component <italic>Pf</italic>PTRAMP (H8) (<xref rid="fig5" ref-type="fig">Figure 5D</xref>). Nanobodies targeting the PCRCR complex component CSS (D2) showed a slight, but non-significant increase in invasion-inhibitory activity in the absence of <italic>Pf</italic>MSP2 (1.4-fold increase; IC<sub>50</sub> value for <italic>Pf</italic>3D7 WT is 57 Î¼g/mL; IC<sub>50</sub> value for <italic>Pf</italic>3D7 ÎMSP2 is 42 Î¼g/mL; p=0.3; <xref rid="fig5" ref-type="fig">Figure 5E</xref>). However, the <italic>Pf</italic>3D7 ÎMSP2 specific increase in invasion-inhibitory activity was amplified with the addition of the human Fc domain to the anti-CSS nanobody (D2-Fc) to be 3-fold greater for <italic>Pf</italic>3D7 ÎMSP2 parasites (IC<sub>50</sub> <italic>Pf</italic>3D7 WT 138 Î¼g/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 46 Î¼g/mL; p=0.0001; <xref rid="fig5" ref-type="fig">Figure 5F</xref>).</p>
<p>The glycosaminoglycan heparin is a specific inhibitor of invasion and has been observed to bind to the 42 kDa C-terminal region of <italic>Pf</italic>MSP1 the most abundant GPI-anchored protein on the merozoite surface, marking this as a possible mechanism for its invasion inhibitory activity (<xref ref-type="bibr" rid="c15">Boyle et al., 2010a</xref>). However, the highly charged state of heparin means that it could block invasion through binding additional proteins. When tested against <italic>Pf</italic>3D7 WT and <italic>Pf</italic>3D7 ÎMSP2 parasites, we observed a small increase in inhibitory potency of heparin for parasites lacking <italic>Pf</italic>MSP2 (1.4-fold; IC<sub>50</sub> <italic>Pf</italic>3D7 WT 0.65 IU/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 0.47 IU/mL; p=0.0003; <xref rid="fig5" ref-type="fig">Figure 5G</xref>). We next tested rabbit antibodies raised against the C-terminal 19 kDa fragment of <italic>Pf</italic>MSP1. We found a small but non-significant trend towards increased inhibition of growth in parasites that lacked <italic>Pf</italic>MSP2 across repeat experiments (<xref rid="fig5" ref-type="fig">Figure 5H</xref>). These data suggest that loss of <italic>Pf</italic>MSP2 can impact on the invasion-inhibitory potency of some antibodies that target secreted or surface antigens.</p>
</sec>
<sec id="s2e">
<title>Loss of <italic>Pf</italic>MSP2 consistently potentiates AMA1 invasion inhibitory antibodies</title>
<p>Subsequent to <italic>Pf</italic>Rh5 -basigin binding in the steps of merozoite invasion is the formation of the tight-junction between <italic>Pf</italic>AMA1, secreted from the micronemes onto the merozoite surface, and the rhoptry neck protein <italic>Pf</italic>RON2, which is inserted into the RBC membrane (<xref ref-type="bibr" rid="c38">Lamarque et al., 2011</xref>; <xref ref-type="bibr" rid="c66">Srinivasan et al., 2011</xref>). In lines where <italic>Pf</italic>MSP2 was disrupted, we found a consistent potentiation of antibodies that had anti-<italic>Pf</italic>AMA1 invasion-inhibitory activity. Invasion-inhibitory polyclonal rabbit serum antibodies and purified immunoglobulin raised against <italic>Pf</italic>AMA1 of <italic>Pf</italic>3D7 and <italic>Pf</italic>W2mef (isogenic to <italic>Pf</italic>Dd2), which express different alleles of both <italic>Pf</italic>MSP2 and <italic>Pf</italic>AMA1, were found to be more inhibitory with <italic>Pf</italic>MSP2 knock-out (<xref rid="fig6" ref-type="fig">Figure 6A</xref> and <xref rid="fig6" ref-type="fig">B</xref>). The polyclonal antibody with the greatest potentiation of inhibitory activity was an IgG preparation purified from a rabbit antiserum raised against <italic>Pf</italic>W2mef AMA1. This had a 3-fold increased potency against <italic>Pf</italic>Dd2 ÎMSP2 compared to <italic>Pf</italic>Dd2 WT (IC<sub>50</sub> <italic>Pf</italic>Dd2 WT 0.015 mg/mL; IC<sub>50</sub> <italic>Pf</italic>Dd2 ÎMSP2 0.005 mg/mL; p&lt;0.0001) over two cycles of growth (<xref rid="fig6" ref-type="fig">Figure 6B, C</xref>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Absence of <italic>Pf</italic>MSP2 from the merozoite surface impacts invasion inhibition by <italic>Pf</italic>AMA1 antibodies.</title>
<p><italic>Pf</italic>3D7 <bold>(A, D-F, H, I)</bold> and <italic>Pf</italic>Dd2 <bold>(B, C, G)</bold> express different <italic>Pf</italic>MSP2 alleles and different <italic>Pf</italic>AMA1 alleles, yet both showed altered anti-AMA1 antibody growth inhibition in the absence of <italic>Pf</italic>MSP2. The effect was seen with serum (<bold>A-B</bold>; different vaccinated rabbit (Rb) sera identified by numbers), purified rabbit and mouse monoclonal (mAb) antibodies <bold>(C-E)</bold> and i-bodies (ibA) <bold>(F-J)</bold>. Final parasitaemia was determined by flow cytometry and compared to control. Graph displays mean Â± S.D. of three or four independent experiments. Significance was determined by unpaired t-test when only a single concentration point was tested and for IC<sub>50</sub> comparisons an extra Sum-of-Squares F Test (best-fit LogIC<sub>50</sub>) was performed with p&lt; 0.05 deemed significant.</p></caption>
<graphic xlink:href="653866v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The mouse 1F9 (binds to the RON2 binding pocket and polymorphic loop 1d (<xref ref-type="bibr" rid="c17">Coley et al., 2007</xref>)) and rat 4G2 (binds to a conserved epitope in the ectodomain (<xref ref-type="bibr" rid="c37">Kocken et al., 1998</xref>)) monoclonal antibodies have been shown to target different regions of <italic>Pf</italic>AMA1 and exhibit selective inhibition against <italic>Pf</italic>3D7 AMA1. Here we found potentiation of invasion inhibitory activity with <italic>Pf</italic>3D7 MSP2 knock-out for both 1F9 (2.1-fold; IC<sub>50</sub> <italic>Pf</italic>3D7 WT 0.27 mg/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 0.13 mg/mL; p&lt;0.0001; <xref rid="fig6" ref-type="fig">Figure 6D</xref>) and 4G2 (3.2-fold; IC<sub>50</sub> <italic>Pf</italic>3D7 WT 1.15 mg/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 0.36 mg/mL; p&lt;0.0001; <xref rid="fig6" ref-type="fig">Figure 6E</xref>).</p>
<p>We also tested the invasion inhibitory effect of i-bodies, which are smaller single-domain antibody-like molecules inspired from the shark variable new antigen receptor (V<sub>NAR</sub>) (<xref ref-type="bibr" rid="c34">Griffiths et al., 2018</xref>, <xref ref-type="bibr" rid="c33">2016</xref>). When we tested the i-body WD34 (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>) which binds a highly conserved epitope that includes the <italic>Pf</italic>RON2-binding pocket on <italic>Pf</italic>AMA1, we observed a small potentiation of <italic>Pf</italic>AMA1 specific activity with knock-out of <italic>Pf</italic>MSP2 in <italic>Pf</italic>3D7 (1.3-fold; IC<sub>50</sub> <italic>Pf</italic>3D7 WT 0.012 mg/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 0.009 mg/mL; p=0.08 <xref rid="fig6" ref-type="fig">Figure 6F</xref>). Given WD34 was also found to be inhibitory to growth of W2mef parasites (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>) we also tested its activity against our <italic>Pf</italic>Dd2 ÎMSP2 parasites and found potentiation of invasion inhibitory activity with loss of MSP2 in <italic>Pf</italic>Dd2 parasites (2-fold; IC<sub>50</sub> <italic>Pf</italic>Dd2 WT 0.016 mg/mL; IC<sub>50</sub> <italic>Pf</italic>Dd2 ÎMSP2 0.008 mg/mL; p=0.004 <xref rid="fig6" ref-type="fig">Figure 6G</xref>). As was observed for the anti-CSS nanobody, addition of a human Fc domain to WD34 amplified the inhibitory phenotype, with WD34 Fc having a 2.3-fold greater inhibitory activity against <italic>Pf</italic>3D7 ÎMSP2 than against <italic>Pf</italic>3D7 WT (IC<sub>50</sub> <italic>Pf</italic>3D7 WT 0.1 mg/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 0.04 mg/mL; p=0.0004; <xref rid="fig6" ref-type="fig">Figure 6H</xref>). A second i-body, WD33 (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>), which binds AMA1 between domain II and domain III, had very limited invasion inhibitory activity against <italic>Pf</italic>3D7 parasites and did not show improved potency with knock-out of <italic>Pf</italic>3D7 MSP2 (0.9-fold; IC<sub>50</sub> <italic>Pf</italic>3D7 WT 1.02 mg/mL; IC<sub>50</sub> <italic>Pf</italic>3D7 ÎMSP2 1.1 mg/mL; p=0.8; <xref rid="fig6" ref-type="fig">Figure 6I</xref>). Although the limited inhibitory activity for WD33 tagged with the Fc receptor prevented us determining an IC<sub>50</sub> at the concentrations feasible to test, there was no increased inhibition of <italic>Pf</italic>3D7 ÎMSP2 parasites compared to the low level seen with <italic>Pf</italic>3D7 WT parasites (data not shown). These data suggest that the potentiation of <italic>Pf</italic>AMA1 targeted antibody inhibition with MSP2 knock-out is <italic>Pf</italic>AMA1 epitope dependent.</p>
<p>To account for the differences in i-body sizes, we compared the WD34 and WD34 Fc i-bodies on a molar basis and found that they had similar activities against <italic>Pf</italic>3D7 MSP2 WT parasites (IC<sub>50</sub> 0.94 Î¼M and 1 Î¼M respectively) indicating that the Fc-tag itself did not modify epitope binding properties. Rather, it is the absence of <italic>Pf</italic>MSP2 that results in increased inhibition of AMA1 function by WD34, and this is further potentiated by antibody size.</p>
<p>In light of these results, we hypothesised that removal of <italic>Pf</italic>MSP2 may improve antibody access to other antigens that are targets of inhibitory antibodies. To assess whether this was the case, we first tested whether increased <italic>Pf</italic>AMA1 polyclonal antibody binding to the surface of merozoites could be observed for <italic>Pf</italic>3D7 ÎMSP2 compared to <italic>Pf</italic>3D7 MSP2 WT parasites using a fluorescently tagged WD34 i-body (WD34-mCherry) for quantitative immunofluorescence assays of late stage schizonts labelled with a single incubation and wash step. We observed WD34-mCherry to have a significantly higher mean fluorescence intensity for <italic>Pf</italic>3D7 ÎMSP2 compared to <italic>Pf</italic>3D7 WT (<xref rid="fig7" ref-type="fig">Figure 7A</xref>), supporting that the <italic>Pf</italic>AMA1 i-bodies may have better access in the absence of <italic>Pf</italic>MSP2. As a control, we tested labelling using a fluorescently tagged WD33 i-body which binds to AMA1 (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>), but we found did not have improved inhibitory activity in the absence of MSP2 (<xref rid="fig6" ref-type="fig">Figure 6I</xref>). Mirroring the results of the growth assay, there was no difference observed for WD33-eGFP binding fluorescence for <italic>Pf</italic>3D7 ÎMSP2 compared to <italic>Pf</italic>3D7 WT parasites (<xref rid="fig7" ref-type="fig">Figure 7B</xref>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>Quantitative fluorescence microscopy to assess whether differential binding may explain the increased potency of anti-<italic>Pf</italic>AMA1 invasion-inhibitory antibodies in the absence of <italic>Pf</italic>MSP2.</title>
<p>Fluorescence intensity of fluorescently tagged anti-<italic>Pf</italic>AMA1 i-body (ibA) WD34-mCherry <bold>(A)</bold> and WD33-eGFP <bold>(B)</bold> for both <italic>Pf</italic>3D7 WT and <italic>Pf</italic>3D7 ÎMSP2, with a representative image for i-body WD34-mCherry. Nucleus in blue, i-body signal in red. Scale bar = 4 Âµm. Two independent experiments were performed with significance determined by unpaired t-test with p&lt; 0.05 deemed significant. The lower overall mCherry signal required a higher antibody concentration (240 ng/mL) to have a comparable intensity measure to the eGFP tagged antibody (120 ng/mL) for <italic>Pf</italic>3D7 WT merozoites. <bold>(C)</bold> Read-out of the Surface plasmon resonance (SPR) antibody on-rate (association constant) for anti-<italic>Pf</italic>AMA1 mAb 4G2 and i-body WD34-Fc binding to <italic>Pf</italic>AMA1 in the presence or absence of <italic>Pf</italic>MSP2 protein. Data represents the mean of 3 experiments with significance determined by unpaired t-test with p&lt; 0.05 deemed significant. <bold>(D)</bold> ELISA based assessment of the anti-<italic>Pf</italic>AMA1 mAb 4G2 and i-body WD34-Fc antibody binding levels to recombinant <italic>Pf</italic>3D7 AMA1 in the presence or absence of recombinant <italic>Pf</italic>3D7 MSP2. PBS control demonstrates background fluorescence. Dashed orange line provides a guide for peak absorbance levels. Anti-<italic>Pf</italic>MSP2 mAb shows increasing concentrations of <italic>Pf</italic>MSP2 protein results in decreased binding of mAb 4G2 and i-body WD34-Fc. Data represents the mean of 3 experiments and error bars are Â±S.D.</p></caption>
<graphic xlink:href="653866v1_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We next explored whether the addition of recombinant <italic>Pf</italic>MSP2 could impact on the inhibitory antibody binding on-rate against substrate-bound <italic>Pf</italic>AMA1 recombinant protein using Surface Plasmon Resonance (SPR). For the anti-<italic>Pf</italic>AMA1 targeting mAb 4G2, there was a non-significant trend toward a lower on-rate in the presence of recombinant <italic>Pf</italic>MSP2 (<xref rid="fig7" ref-type="fig">Figure 7C</xref>). For the i-body WD34-Fc, there was minimal difference in detectable <italic>Pf</italic>AMA1 binding to <italic>Pf</italic>AMA1 in the presence or absence of <italic>Pf</italic>MSP2 (<xref rid="fig7" ref-type="fig">Figure 7C</xref>). Using a similar principle of testing antibody binding to substrate-bound <italic>Pf</italic>AMA1 protein in the presence, or absence of increasing concentrations of <italic>Pf</italic>MSP2, we assessed changes in levels of anti-<italic>Pf</italic>AMA1 antibody binding using an enzyme linked immunosorbent assay (ELISA). With increasing concentrations of <italic>Pf</italic>MSP2 added to wells coated with AMA1, we found decreased binding of anti-<italic>Pf</italic>AMA1 mAb 4G2 and i-body WD34-Fc by ELISA (<xref rid="fig7" ref-type="fig">Figure 7D</xref>). Interestingly, <italic>Pf</italic>MSP2 concentrations â¤0.31 Î¼g/mL, an antigen concentration below the level that could be detected by an MSP2 mAb, were enough to impact on the binding of <italic>Pf</italic>AMA1 antibodies. By looking at the impacts of removing <italic>Pf</italic>MSP2 from the merozoite surface, or adding this protein in to recombinant assays, these data provide additional support that inhibitory antibodies targeting <italic>Pf</italic>AMA1 bind at a higher rate in the absence of <italic>Pf</italic>MSP2.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Despite decades of research and interest, the function of most merozoite surface proteins remains unclear and targeting merozoite antigens in vaccine development has not achieved high efficacy in clinical trials. Additionally, it has generally proven difficult to generate highly inhibitory antibodies through vaccination with merozoite antigens. <italic>Pf</italic>MSP2 is one of the most abundant proteins on the merozoite surface, has shown promise as a vaccine candidate and is an established target of protective cytophilic antibodies (<xref ref-type="bibr" rid="c14">Boyle et al., 2015</xref>; <xref ref-type="bibr" rid="c31">Genton et al., 2002</xref>; <xref ref-type="bibr" rid="c48">McCarthy et al., 2011</xref>; <xref ref-type="bibr" rid="c51">Osier et al., 2014</xref>, <xref ref-type="bibr" rid="c52">2010</xref>). However, its function remains unclear. Our findings here suggest that <italic>Pf</italic>MSP2 does not have an essential role in invasion <italic>in vitro</italic>, but can modulate the sensitivity of merozoites to inhibitory antibodies targeting other antigens.</p>
<p>Despite its abundance on the merozoite surface and previous work suggesting a role in RBC invasion, we found merozoites invade normally in the absence of this protein after gene deletion. This does not exclude a role for <italic>Pf</italic>MSP2 <italic>in vivo</italic> where there are additional pressures, such as immune-effector mechanisms and flow dynamics, on merozoite invasion. However, given we have knocked-out <italic>Pf</italic>MSP2 from two different <italic>P. falciparum</italic> isolates, our findings do not currently support a major role for <italic>Pf</italic>MSP2 in the mechanics of merozoite invasion. Thus, it appears that the function of the two most abundant proteins on the merozoite surface, <italic>Pf</italic>MSP1 (<xref ref-type="bibr" rid="c20">Das et al., 2015</xref>; <xref ref-type="bibr" rid="c36">Kals et al., 2024</xref>) and <italic>Pf</italic>MSP2, are not directly linked to merozoite binding to the RBC and subsequent invasion. Deletion of MSP2 did lead to significant changes in the expression of several genes, but there were no proteins with a clear link to merozoite invasion and the biological relevance of these changes is not currently understood and requires future investigation.</p>
<p>Both rabbit polyclonal and mouse monoclonal anti-<italic>Pf</italic>AMA1 antibodies tested were consistently more inhibitory in the absence of <italic>Pf</italic>MSP2. Of the two <italic>Pf</italic>AMA1 targeting i-bodies tested (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>), the most potent WD34 was also more potent in the absence of <italic>Pf</italic>MSP2, with this activity increasing significantly with the â¼5.6-fold increase in size that occurred upon addition of a mouse Fc region. Similarly, activity of a nanobody targeting the PCRCR complex protein CSS showed increased potency in the absence of <italic>Pf</italic>MSP2, and again this was increased further with antibody enlargement through addition of an Fc region. These data suggest that <italic>Pf</italic>MSP2 may act to dampen the inhibitory activity of antibodies targeting other antigens on the surface of the merozoite. Such immune dampening (called conformational masking) by intrinsically disordered proteins, or protein regions, of host-cell invasion related proteins has recently been demonstrated by modelling and gene-editing studies in the viral pathogens HIV and HCV, respectively (<xref ref-type="bibr" rid="c40">Li et al., 2024</xref>; <xref ref-type="bibr" rid="c68">Stejskal et al., 2022</xref>). These studies, along with our demonstration of increase antibody inhibitory efficacy with loss of the intrinsically disordered <italic>Pf</italic>MSP2, support that this may be a widespread approach used by pathogens to protect important protein functional sites from inhibitory antibodies.</p>
<p>A role in immune evasion has previously been suggested for <italic>Pf</italic>MSP2 and speculatively an alternate explanation for the sensitisation observed is that this protein may shield key <italic>Pf</italic>AMA1 epitopes from antibody inhibition. For the <italic>P. falciparum</italic> 3D7 line, we found that <italic>Pf</italic>MSP2 knock-out led to higher <italic>Pf</italic>AMA1 binding as measured by increased fluorescence intensity for the mCherry tagged i-body WD34 in the absence of <italic>Pf</italic>MSP2. Using a solid-phase model and titrating recombinant <italic>Pf</italic>MSP2, we found that increasing concentrations of <italic>Pf</italic>MSP2 reduced binding of an anti-<italic>Pf</italic>AMA1 mAb and i-body, even at concentrations where <italic>Pf</italic>MSP2 was not detectable itself by antibodies. These data support that the presence of <italic>Pf</italic>MSP2 may reduce antibody access (masking) to important invasion proteins exposed on the merozoites surface. However, we acknowledge that the antibody-binding assays used (immunofluorescence assays, SPR, ELISA) might not be sensitive enough to observe all potential changes in binding, temporal changes when binding epitopes are exposed or differences in avidity that could lead to increased antibody potency during the course of parasite invasion and growth, and these factors may also contribute. Future studies of the merozoite surface and interactions between proteins may help decipher in full how <italic>Pf</italic>MSP2 is protecting essential merozoite antigens from invasion inhibitory antibody activity and reveal strategies for enhanced vaccine design.</p>
<p>Our observation that loss of <italic>Pf</italic>MSP2 potentiates the invasion-inhibitory activity of antibodies targeting other antigens opens an additional avenue for vaccine development, such as targeting <italic>Pf</italic>MSP2 to interfere with its potential role in immune evasion and thus potentiating antibodies against other merozoite antigens. Additionally, our results suggest that vaccines based on <italic>Pf</italic>AMA1 may need to be designed to specifically avoid the effect of <italic>Pf</italic>MSP2 modulating inhibitory antibodies, such as focussing on specific epitopes or structural features. To date, vaccines based on AMA1 have failed to achieve substantial efficacy (<xref ref-type="bibr" rid="c60">Sagara et al., 2009</xref>; <xref ref-type="bibr" rid="c64">Sheehy et al., 2012</xref>; <xref ref-type="bibr" rid="c71">Thera et al., 2011</xref>). We can speculate that one possible protective mechanism of action of the Combination B vaccine (<xref ref-type="bibr" rid="c31">Genton et al., 2002</xref>; <xref ref-type="bibr" rid="c48">McCarthy et al., 2011</xref>), which combined <italic>Pf</italic>MSP2, <italic>Pf</italic>MSP1 and <italic>Pf</italic>RESA, could be that the inhibitory activity of vaccine-induced antibodies raised against <italic>Pf</italic>MSP2 were then able to potentiate the activity of antibodies targeting other antigens, potentially <italic>Pf</italic>MSP1 which was also a target of the vaccine. Further investigation using the parasite lines developed in this study and a wider panel of antibodies could shed more light on this potentially novel mechanism of vaccine derived antibody efficacy.</p>
<p>The results of this study and work done by <xref ref-type="bibr" rid="c26">Escalante et al. (2022)</xref> demonstrate that MSP2-like sequences are found in the avian malarias <italic>P. galinaceum</italic> and <italic>P. relictum</italic>, which differs from the fields previous understanding that <italic>Pf</italic>MSP2 arose in the <italic>Laverania</italic> lineage of malaria parasites. This observation indicates that MSP2 was likely present in the ancestral malaria parasite before being lost in primate and rodent <italic>Plasmodium</italic> spp. Further insights into the evolution and loss of <italic>Pf</italic>MSP2 are likely to be found with additional whole genome sequences of bird and lizard malaria species. The presence of <italic>msp2</italic>-like sequences in some avian <italic>Plasmodium</italic> species and <italic>Laverania</italic> suggest a retention of <italic>msp2</italic> sequences in the <italic>Laverania</italic> which indicates an important role for MSP2 for these parasites. Indeed, our amino acid and structural prediction level comparison demonstrates that much of the protein properties conserved in the <italic>Laverania</italic> MSP2s are also recognisable, and in many cases conserved, in the avian malaria MSP2s, despite 10 million years of evolutionary divergence. This suggests that having an MSP2-like protein is beneficial for these parasites with very different hosts. However, CRISPR-Cas9 gene editing used in this work has shown that, in contrast to previous work, <italic>Pf</italic>MSP2 is not essential for <italic>P. falciparum</italic> blood stage parasite growth <italic>in vitro</italic>. Our findings raise the possibility that the retention of <italic>Pf</italic>MSP2 in the <italic>Laverania</italic>, and by association potentially the avian malaria parasites, may be linked to its apparent capacity to modulate the impact of antibodies against other merozoite surface-exposed antigens, rather than through a direct mechanistic role in host-cell invasion. If MSP2 was to fulfill such a role in the <italic>Laverania</italic> and avian malaria parasites, it raises the question of whether a similar protective system exists in other <italic>Plasmodium</italic> spp. and what the key protein/s are that fulfil this role in these parasites.</p>
<p>The <italic>Pf</italic>3D7 MSP2 and <italic>Pf</italic>Dd2 MSP2 lines developed in this study will provide useful reagents for investigating the potential of targeting a single, or both, <italic>Pf</italic>MSP2 allelic types with vaccines that elicit different immune responses. These parasites could also be used to explore whether vaccine-induced antibodies against other merozoite antigens could also be potentiated if any immune evasion mechanism provided by <italic>Pf</italic>MSP2 is removed. This may be achievable with a combination vaccine or through targeting an epitope of another merozoite vaccine candidate that is not protected by <italic>Pf</italic>MSP2. Such information, investigated using the <italic>Pf</italic>MSP2 knock-out parasites developed in this study, could be useful in prioritising vaccine candidates, specific epitopes and combinations that target the merozoite.</p>
</sec>
<sec id="s4">
<title>Conclusion</title>
<p>Advancements in gene-editing techniques in <italic>P. falciparum</italic> have allowed us to show for the first time, and contrary to previous work, that <italic>Pf</italic>MSP2 is not essential for <italic>P. falciparum</italic> growth <italic>in vitro</italic>. Instead, we present a new concept that MSP2 can modulate the activity of invasion-inhibitory antibodies and may have evolved for this purpose. It is possible that other merozoite surface proteins may have similar roles and should be investigated in future studies. Our observation that loss of <italic>Pf</italic>MSP2 potentiates the inhibitory activity of antibodies targeting other merozoite surface exposed proteins reveals a new avenue to explore in vaccine development by blocking or bypassing this function to improve the activity of vaccines targeting these antigens.</p>
</sec>
<sec id="s5">
<title>Materials and Methods</title>
<sec id="s5a">
<title>Bioinformatic analysis of <italic>Pf</italic>MSP2, <italic>Pf</italic>MSP4 and <italic>Pf</italic>MSP5 like proteins in <italic>Plasmodium</italic> spp</title>
<p>The PlasmoDB database (<xref ref-type="bibr" rid="c6">Aurrecoechea et al., 2009</xref>) was used to identify in the available <italic>Plasmodium</italic> genomes the region between Adenylosuccinate lyase (PF3D7_0206700) and a conserved protein of unknown function (PF3D7_0207100) where <italic>Pf</italic>MSP2, <italic>Pf</italic>MSP4 and <italic>Pf</italic>MSP5 are localised in <italic>P. falciparum</italic>. All annotated MSP2, MSP4 and MSP5 protein sequences were downloaded. Translated sequences of unannotated genes and putative annotations in this region were also downloaded and aligned using the MUSCLE alignment tool MEGA11: Molecular Evolutionary Genetics Analysis version 11 (<xref ref-type="bibr" rid="c69">Tamura et al., 2021</xref>) or the Geneious Prime 2019.2.1 MUSCLE alignment tool (Biomatters Ltd.) and determined to be MSP2, MSP4 or MSP5 based on sequence similarity in the conserved regions of these genes. A BLAST (NCBI) search with the N-terminal and C-terminal conserved regions of MSP2 was also performed to capture any sequences missed by the above approach. A maximum likelihood phylogenetic tree of identified MSP2 sequences was generated using the default maximum likelihood settings of MEGA11 with 500 bootstraps and the <italic>P. gallinaceum</italic> MSP2 as an outgroup.</p>
</sec>
<sec id="s5b">
<title>Modelling of MSP structure across Plasmodium spp. using Alpha-fold</title>
<p>In order to obtain models of the 3-dimensional protein structures of MSP2 for <italic>P. falciparum</italic>, <italic>P. reichenowi</italic>, <italic>P. billcollinsi</italic>, <italic>P. adleri</italic>, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic>, we first removed the predicted N-terminal signal sequences and C-terminal GPI anchor sequence. The resulting sequences were submitted to AlphaFold2 (<xref ref-type="bibr" rid="c35">Jumper et al., 2021</xref>). The resulting models were subsequently analysed and visualised using PyMOL 2.4.0 (SchrÃ¶dinger, USA).</p>
</sec>
<sec id="s5c">
<title>Culture and synchronisation of <italic>P. falciparum</italic></title>
<p><italic>Plasmodium falciparum</italic> 3D7 and Dd2 was cultured in RPMI-HEPES media (Gibco) containing 0.5% Albumax ll (Gibco), 25 Î¼M Gentamicin (Gibco), 367 Î¼M hypoxanthine (Sigma Aldrich), 2 mM L-Glutamax (Gibco), 0.17% sodium bicarbonate (Sigma Aldrich) and O positive human red blood cells (Lifeblood, Australia) at 3% parasitemia, 3% haematocrit. Cultures were grown at 37Â°C under 1% oxygen, 5% CO<sub>2</sub> (BOC gas), in a humidified chamber. For gene-edited lines, WR99210 (Jakobus Pharmaceuticals) was added to culture media. Sorbitol lysis (5%) (Sigma Aldrich) to select for ring-stage parasites, Percoll Plus (Sigma Aldrich) selection of late-stage parasites and heparin treatment (Pfizer) (<xref ref-type="bibr" rid="c16">Boyle et al., 2010b</xref>) were used to maintain synchronicity of parasite cultures.</p>
</sec>
<sec id="s5d">
<title>Generation of <italic>Pf</italic>MSP2 knockout line using CRISPR Cas9</title>
<p>Briefly, a flank region incorporating the 5â region upstream of <italic>Pf</italic>MSP2, the first 44 amino acids of the protein, and a flank of the region immediately 3â of <italic>Pf</italic>MSP2 was inserted into the pCC1 plasmid by restriction enzyme cloning. A 20 bp guide sequence was designed using EuPaGDT (<xref ref-type="bibr" rid="c53">Peng and Tarleton, 2015</xref>), annealed and inserted in the pUF_Cas9 plasmid by infusion cloning (Takara Bio). pUF_Cas9 guide plasmid (20 Î¼g) and pCC1 <italic>Pf</italic>MSP2 repair plasmid (60 Î¼g) was transfected directly into <italic>P. falciparum</italic> schizonts. Early schizonts were purified using a 70% percoll gradient and treated for 4 hrs with compound 1 (<xref ref-type="bibr" rid="c70">Taylor et al., 2010</xref>) at 2 Î¼M. After incubation treated schizonts were washed twice and left shaking for 20 minutes before pelleting and resuspension in Complete Cytomix (plasmids plus 0.895% KCl, 0.0017% CaCl<sub>2</sub>, 0.076% EGTA, 0.102% MgCl<sub>2</sub>, 0.0871% K<sub>2</sub>HPO<sub>4</sub>, 0.068% KH<sub>2</sub>PO<sub>4</sub>, 0.708% HEPES). Schizonts were electroporated in 0.2 cm cuvettes (Biorad) at 800 V and 25 Î¼F. Electroporated schizonts were mixed with warmed media and fresh RBCs and shaken to promote invasion for 20 minutes after which they were placed in a culture dish. Transfected parasites were then treated with WR99210 to select for integration of the hDHFR drug selection cassette and MSP2 knock-out.</p>
<p>To confirm integration gDNA was collected by saponin lysis of schizont stage parasite culture and gDNA extracted using the PureLink Genomic DNA Mini Kit (Invitrogen) as per manufacturerâs instructions. Integration of the <italic>Pf</italic>MSP2 knockout construct into a portion of parasites was confirmed by PCR (<xref ref-type="table" rid="tbls1">Supplementary Table 1</xref>). Once confirmed cultures were cycled on and off WR99210 (Jakobus Pharmaceuticals) and 1 Î¼M 5FC (Sigma Aldrich) to select for integrated parasites no longer expressing the guide plasmid. Limited dilution cloning was then performed to obtain parasite clones which had integrated the knockout construct.</p>
</sec>
<sec id="s5e">
<title>Western blotting to detect <italic>Pf</italic>MSP2</title>
<p>Synchronised schizonts were harvested and the RBCs lysed by saponin. Briefly â¼10 mL schizont (38-44 hrs) culture was lysed on ice for 10 minutes with 0.15% w/v saponin before pelleting by centrifugation and washing once in 0.075% w/v saponin followed by three washes in PBS containing protease inhibitors (CÃmplete, Roche). Saponin treated schizont pellets were treated with DNAsel (Qiagen) for 10 minutes at room temperature before resuspension in reducing sample buffer (0.125 M Tris-HCL, 4% SDS, 20% glycerol, 10% beta-mercaptoethanol and 0.002% bromophenol blue). Proteins were separated by size using SDS-PAGE 4-12% Bis-Tris Gels (Bolt, Invitrogen) at 110V for 80 minutes before transfer to a nitrocellulose membrane (iBlot, Invitrogen) at 20V for 7 minutes. Blots were blocked from 1 hr to overnight in 3% skim milk PBS (Sigma Aldrich) before incubation with primary antibodies (1/75000 mouse 2F2 anti-<italic>Pf</italic>MSP2 3D7 (<xref ref-type="table" rid="tbls2">Supplementary Table 2</xref>; (<xref ref-type="bibr" rid="c1">Adda et al., 2012</xref>)) and 1/75000 rabbit anti-<italic>Plasmodium</italic> aldolase (Abcam) or 1/75000 rabbit anti-FC27 and 1/10000 mouse anti-EXP2 (a gift of Paul Gilson, Burnet Institute, Melbourne) for 1-2 hrs. IRDye 800CW goat anti-mouse (1/4000, LI-COR Biosciences) or IRDye 680RD goat anti-rabbit (1/4000, LI-COR Biosciences) secondary antibodies were used for detection on the Odyssey Infrared imaging system (LI-COR Biosciences). Quantification was performed using Image Studio Lite 5.2.5 (LI-COR Biosciences).</p>
</sec>
<sec id="s5f">
<title>Quantification of parasite expansion rate and invasion inhibition</title>
<p>Potential growth defects resulting from gene editing was assessed by flow cytometry. The initial parasitemia of cultures was determined by flow cytometry and then measured again after either 48 hrs or 96 hrs of growth. To determine parasitemia by flow cytometry Ethidium Bromide (10 Î¼g/mL BioRad) was added to 50 Î¼L of 1% haematocrit culture for 30 mins to allow for staining of parasite DNA. The stain was washed off and wells resuspended in 200Î¼L of PBS. Data was collected on a BD Accuri C6 Plus Flow Cytometer (BD Biosciences) and analysed on FlowJo (FlowJo LLC). Briefly, forward scatter and side scatter was used to determine the RBC population. From this population infected RBCs were gated on as highly fluorescent in the PE channel. Final parasitemia was compared back to initial parasitemia to determine the fold increase in parasitemia for each line.</p>
<p>To examine the invasion inhibitory effect of antibodies (<xref ref-type="table" rid="tbls2">Supplementary Table 2</xref>), 5 Î¼L of potential inhibitor was mixed with 45 Î¼L of 0.2% schizont parasitemia at 1% haematocrit for 96 hrs before end parasitemia was determined by flow cytometry. Data is displayed as % Growth of media only controls for each line.</p>
<p>To examine differences in RBC receptor preference RBCs were treated with different enzymes that cleave different residues of RBC receptors which is used as a marker for which RBC receptor/s are preferred by <italic>P. falciparum</italic> (<xref ref-type="bibr" rid="c24">Duraisingh et al., 2003</xref>). Infected RBCs at 1% ring stage parasitemia were washed three times in RPMI-HEPES to remove excess protein. Packed RBCs (20 Î¼L) at 1% parasitemia were then resuspended with 5X RBC volume of pre-warmed enzymes at desired concentration (<xref ref-type="table" rid="tbls3">Supplementary Table 3</xref>). RBC-enzyme mix was incubated at 37Â°C for 45 mins with rotation to keep RBCs resuspended. Following incubation, RBCs were washed three times and added to fresh complete media at 1% haematocrit in a U-bottom 96 well plate in technical duplicate. Plates were incubated for 72 hrs, sufficient time for <italic>P. falciparum</italic> to complete one full cycle of growth and reach trophozoite stage again. Final parasitemia was determined by flow cytometry, as detailed above, and compared to non-treated controls. IC<sub>50</sub> calculations data was log transformed then a nonliner regression log-(inhibitor)-versus-response curve was calculated with Extra Sum-of-Squares F Test (best-fit LogIC<sub>50</sub>) used to compared IC<sub>50</sub>s between conditions.</p>
</sec>
<sec id="s5g">
<title>Immunofluorescence assay of Wildtype and <italic>Pf</italic>MSP2 KO parasites</title>
<p>Schizonts â¼38 hrs old were treated with E64 (Sigma-Aldrich) for 5 hrs to allow development of very mature schizonts desired for imaging. After E64 treatment, parasite cultures were fixed in 4% v/v paraformaledehyde (PFA, Sigma-Aldrich), 0.0075% v/v glutaraldehyde (pH 7.5, Electron Microscopy Sciences) solution for 30 min at room temperature shaking gently. Fixed parasites were washed in 1X PBS and then resuspended in PBS at 1% haematocrit. Coverslips (#1.5H high-precision coverslips, Carl Zeiss, Oberkochen, Germany) were coated in 0.01% Poly-L-lysine (Sigma Aldrich) for 1 hr at room temperature, washed in miliQ water before the fixed parasite culture was allowed to adhere for 1 hr. Cells were permeabilised by 0.1% Triton X-100 PBS for 10 mins before blocking for 1 hr to overnight in 3% BSA 0.05% Tween 20 PBS. Primary antibodies were diluted in 1% BSA 0.05% Tween 20 PBS and incubated for 2 hrs. Coverslips were washed in 0.05% Tween 20 PBS three times before incubation with the secondary antibody (1/500 goat anti-chicken/mouse/rabbit Alexa Fluor coupled secondary antibodies â488 nm, 594 nm, 647 nm; Life Technologies) for 1 hr. After the secondary antibody was washed off coverslips underwent a secondary fix in 4% v/v PFA, 0.0075% v/v glutaraldehyde for 5 mins. The fixative was washed off and the coverslips dehydrated with sequential 3 min ethanol treatment (70%, 90% and 100%). Coverslips were allowed to dry and mounted with ProLong Gold antifade solution (refractive index 1.4) which contains 4â, 6-diamidino-2phenylindole, dihydrochloride (DAPI) (ThermoFisher Scientific) and allowed to set overnight. Imaging was performed on the Zeiss LSM 800 using the Airyscan super-resolution mode (Carl Zeiss, Obekochen, Germany).</p>
</sec>
<sec id="s5h">
<title>Live cell microscopic analysis of merozoite RBC invasion</title>
<p>Highly synchronised <italic>Pf</italic>Dd2 and <italic>Pf</italic>Dd2 ÎMSP2 parasites at schizont stages were adjusted to 0.25% Haematocrit in complete culture medium. A volume of 200 Î¼L was added to a well of an iBidi 15 Î¼-Slide 8 well, glass bottom slide (iBidi 80827) and the slide was promptly returned to sit on a prewarmed water block within a gassed box and left to incubate at 37Â°C to allow iRBCs to settle. The slide was then transported directly to a prewarmed Nikon TiE microscope with an environmental chamber heated to 37<sup>Î¿</sup>C and gas mixture of 1% O<sub>2</sub>, 5% CO<sub>2</sub> and 94% nitrogen. Filming was conducted using either a 60X water or 100X oil objective. Differential interference contrast (DIC) imaging was captured at 3 â 3.5 Volts with a camera exposure of 60 â 180 milliseconds.</p>
<p>Captured footage was processed using the Nikon analysis software (NIS-Elements AR Analysis version 5.21.01) and analysis of the schizont rupture and merozoite invasion events was performed manually. The merozoites which invaded successfully were tracked and attachment time, reorientation time (if obvious), deformation start and end times, the deformation score (<xref ref-type="bibr" rid="c72">Weiss et al., 2015</xref>; <xref ref-type="bibr" rid="c74">Wilson et al., 2015</xref>), invasion initiation and completion times and echinocytosis start times were recorded.</p>
</sec>
<sec id="s5i">
<title>RNA extraction</title>
<p>Highly synchronised cultures were pelleted, resuspended in TriZol (Invitrogen) and incubated for 5 minutes at 37Â°C. Chloroform (Sigma Aldrich) was added, mixed and then spun at 12,000g for 30 minutes at 4Â°C. Supernatant was collected and mixed with an equal volume of 70% Ethanol and processed using the RNeasy Kit (Qiagen) to extract purified RNA. RNA was DNAse l (Qiagen) treated for 30 mins at room temperature and cleaned up on RNeasy columns according to the manufacturers protocol. Absence of gDNA was checked by qPCR of gDNA with primers (<italic>Pf</italic>SUB1) and DNAse I treatment repeated if necessary.</p>
</sec>
<sec id="s5j">
<title>qPCR of gene expression in schizonts</title>
<p>DNAse treated RNA was added to 40 mM dNTPs (Qiagen), 0.4 mg/mL random hexamer (Qiagen) and incubated at 65Â°C for 5 mins. After incubation 5x Superscript Buffer (Invitrogen), 100 mM DTT (Invitrogen), 40 U/Î¼L RNAseOUT (Invitrogen) and 200 Î¼/mL Superscript lll Reverse Transcriptase (Invitrogen) was added and cycled 25Â°C 5 mins, 50Â°C for 60 mins and 70Â°C for 15 mins. Primers (<xref ref-type="table" rid="tbls4">Supplementary Table 4</xref>) were designed to detect <italic>Pf</italic>MSP2, <italic>Pf</italic>MSP4, <italic>Pf</italic>MSP5, <italic>Pf</italic>SUB1 and Fructose Bisphosphate Aldolase as a reference gene (<xref ref-type="bibr" rid="c61">Salanti et al., 2003</xref>). qPCR was performed on cDNA from WT and knockout parasites with PowerUp SYBR Green Master Mix (Applied Biosystems) and cycling parameters; 95Â°C for 10 mins followed by 40 cycles 95Â°C for 15 mins, 60Â°C for 14 mins before a dissociation step at 95Â°C for 2 mins followed by 60Â°C for 2 mins with a 2% ramp to 95Â°C for 2 mins on the QuantStudio 7 Flex System (ThermoFisher). qPCR was performed in triplicate for each of the three independent experiments. Change in gene expression in knockout lines compared to WT was quantified by the 2<sup>-ÎÎCt</sup> method (<xref ref-type="bibr" rid="c43">Livak and Schmittgen, 2001</xref>).</p>
</sec>
<sec id="s5k">
<title>Differential gene expression in <italic>Pf</italic>MSP2 KO compared to WT schizonts</title>
<p>RNA sequencing of the schizont stage transcriptome of <italic>Pf</italic>3D7 MSP2 KO and <italic>Pf</italic>3D7 WT was performed using the Illumina total RNA with Ribo Zero plus for library preparation and sequenced on the NovaSeq 6000 platform with 2Ã150 bp paired end reads (Supplementary Table 5). Reads were aligned to the <italic>Pf</italic>3D7 reference genome (PlasmoDB v61) using STAR aligner (<xref ref-type="bibr" rid="c22">Dobin et al., 2013</xref>). Reads were called using Rsubread FeatureCounts (<xref ref-type="bibr" rid="c41">Liao et al., 2014</xref>) with reads counted by CDS and summarised by gene. Differential gene analysis was performed with DESeq2 (<xref ref-type="bibr" rid="c44">Love et al., 2014</xref>) and visualized in R studio using ggplots2 (<xref ref-type="bibr" rid="c73">Wickham, 2016</xref>).</p>
</sec>
<sec id="s5l">
<title>Quantitative Immunofluorescence assay</title>
<p>Synchronous <italic>Pf</italic>3D7 MSP2 KO and <italic>Pf</italic>3D7 WT parasite cultures were treated with ML10 (<xref ref-type="bibr" rid="c57">RessurreiÃ§Ã£o et al., 2020</xref>) to allow mature schizonts to develop. Thin blood smears were then made and fixed in 100%, â20Â°C methanol for 5 mins. Blocking of smears was performed in 1% BSA PBS, then fluorophore conjugated WD34 (240 ng/mL) and WD33 (120 ng/mL) i-bodies (<xref ref-type="bibr" rid="c5">Angage et al., 2024</xref>) in 1% BSA PBS were added and incubated at room temperature for 1 hr. Smears were then washed, ethanol dehydrated and a coverslip mounted (ProLong Diamond Antifade mountant with DAPI (refractive index 1.47, ThermoFisher Scientific)) and allowed to cure for 48 hrs at room temperature. Fluorescence images were acquired using an Olympus FV3000 confocal microscope equipped with a 100x oil objective (NA 1.4). Quantification of parasite associated fluorescence was performed using a modified image analysis pipeline (<xref ref-type="bibr" rid="c42">Liffner et al., 2020</xref>) implemented in Imaris<sup>TM</sup> (9.9 version) where non-specific background fluorescence was removed using rolling ball background subtraction and a thresholding algorithm applied to the image to generate binary masks, separating objects exceeding the threshold (putative parasites) from the background. Binary masks were further refined to exclude objects smaller or larger than a defined size range (&lt; 3 Î¼m and &gt; 15 Î¼m), corresponding to the expected size of AMA i-body stained schizonts. Following segmentation the surface area containing antibody signal were calculated and these values compared between <italic>Pf</italic>3D7 MSP2 KO and <italic>Pf</italic>3D7 WT parasites.</p>
</sec>
<sec id="s5m">
<title>Surface Plasmon Resonance (SPR) Assay</title>
<p>Surface plasmon resonance (SPR) was employed to determine the association rate constant (K<sub>a</sub>) of AMA1-antibody interactions in the presence of MSP2 using the Biacore T200 system (Cytiva). Flow cells 1, 2, and 3 were activated for 14 minutes using a 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M N-(3-dimethylaminopropyl)-Nâ-ethylcarbodiimide hydrochloride (EDC) at a flow rate of 5 Î¼L/min. Flow cell one was immobilised with bovine serum albumin (BSA) to serve as a reference surface. AMA1 was immobilised at a concentration of 80 Î¼g/mL in 10 mM sodium acetate (pH 4.5) to achieve a surface density of 1000 response units (RU) on flow cells Two and three. MSP2 was co-immobilised in flow cell three to a surface density of 2000 RU. All surfaces were subsequently blocked with a 7-minute injection of 1 M ethanolamine (pH 8.0). Purified antibodies were prepared in PBS containing 0.005% Tween-20 (pH 7.4) and injected over the flow cells at a flow rate of 60 Î¼L/min at 25Â°C. Single-cycle kinetics, using a bivalent analyte model, was applied to analyse the interactions.</p>
</sec>
<sec id="s5n">
<title>Enzyme-Linked Immunosorbent Assay (ELISA)</title>
<p>ELISAs to evaluate the effect of MSP2 on the binding of AMA1-specific antibodies were carried out in a volume of 100 Î¼L per well, either at room temperature for 1 hr or overnight at 4Â°C. All washing steps consisted of three washes with PBS containing 0.1% Tween-20 (PBS-T). Nunc Maxisorp plates (Thermo Fisher Scientific, USA) were coated with AMA1 at a concentration of 0.8 Î¼g/mL, followed by washing and subsequent coating with increasing concentrations of MSP2. Wells were then blocked with 5% (w/v) skim milk in PBS and then incubated for 1 hr at room temperature with the anti-AMA1 antibodies mouse Fc-conjugated WD34 i-body or mouse monoclonal antibody (mAb) 4G2, or with anti-MSP2 mAb 9D8, at a concentration of 2.5 Î¼g/mL. The primary antibody was washed off and the HRP-conjugated secondary antibody (1:5000, Sigma Aldrich) was then applied for 1 hr at room temperature before washing. For signal development to detect bound primary antibodies, wells were incubated with 1-Step<sup>TM</sup> Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific, USA) according to the manufacturers instructions. The reaction was stopped by adding 1 M sulfuric acid, and the absorbance at 450 nm was measured using a microplate reader.</p>
</sec>
<sec id="s5o">
<title>Statistical Analysis</title>
<p>Three independent experiments were performed for all experiments in technical duplicate, unless otherwise stated. Data was graphed and statistical tests performed in Prism GraphPad v9 or R.</p>
</sec>
</sec>
</body>
<back>
<sec>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 1</label>
<caption><title>Alignment of full-length amino acid protein sequences for all <italic>Pf</italic>MSP2 like sequences on PlasmoDB.</title>
<p>Alignment done using MUSCLE alignment with default settings.</p></caption>
<graphic xlink:href="653866v1_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 2</label>
<caption><title>Alignment (Blosum 62) of Amino acid sequences for the N-terminal conserved region of <italic>P. falciparum</italic> 3D7, available <italic>Laverania</italic>, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2 like sequences on PlasmoDB and identified through a BLAST search on the NCBI server.</title>
<p>P. sp. 1, 2 and 3 represent MSP2 sequences identified using a BLAST search that are indicated to be from an unspecified <italic>Laverania</italic> spp. parasite. Amino acids are coloured according to their properties (RasMol).</p></caption>
<graphic xlink:href="653866v1_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 3</label>
<caption><title>Amino Acid sequences for the N-terminal repeat region of <italic>P. falciparum</italic> 3D7, available <italic>Laverania</italic>, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2 like sequences on PlasmoDB and identified through a BLAST search on the NCBI server.</title>
<p>P. sp. 1, 2 and 3 represent MSP2 sequences identified using a BLAST search that are indicated to be from an unspecific <italic>Laverania</italic> spp. parasite. Sequences presented are not aligned, with the exceptions of the 3 <italic>P. reichenowi</italic> and 3 unspecified <italic>Laverania</italic> sequences in order to highlight the conserved sequence despite an insertion. Insertions that are considered to break up the small amino acid and/or repeat structure for the purposes of this comparison are underlined in Black. Respeats, both conserved and degenerate, are underlined in grey. Amino acids are coloured according to their properties (RasMol).</p></caption>
<graphic xlink:href="653866v1_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 4</label>
<caption><title>Alignment of amino acid sequences for the region corresponding to the C-terminal conserved region of <italic>P. falciparum</italic> 3D7, available <italic>Laverania</italic>, <italic>P. relictum</italic> and <italic>P. gallinaceum</italic> MSP2 like sequences on PlasmoDB and identified through a BLAST search on the NCBI server.</title>
<p><italic>P. sp.</italic> 1, 2 and 3 represent MSP2 sequences identified using a BLAST search that are indicated to be from an unspecified <italic>Laverania</italic> spp. parasite. Initial alignment done using Blosum62 with default settings, with subsequent manual modification as required to align to the cysteine residues and other prominent areas of conservation between the <italic>Laverania</italic> and avian malarias. Amino acids are coloured according to their properties (RasMol).</p></caption>
<graphic xlink:href="653866v1_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary Figure 5</label>
<caption><title>Coverage plot (IGV) showing absence of majority of <italic>msp2</italic> in schizont transcriptome of <italic>Pf</italic>3D7 DMSP2 parasites but <italic>msp2</italic> presence in <italic>Pf</italic>3D7 MSP2WT.</title>
<p>Small section of <italic>msp2</italic> transcribe in <italic>Pf</italic>3D7 ÎMSP2 parasites corresponds with the end of the homology region and primarily covers the signal peptide.</p></caption>
<graphic xlink:href="653866v1_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tbls1" orientation="portrait" position="float">
<label>Supplementary Table 1.</label>
<caption><title>Primers used to generate MSP2 KO lines.</title></caption>
<graphic xlink:href="653866v1_tbls1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls2" orientation="portrait" position="float">
<label>Supplementary Table 2.</label>
<caption><title>Antibodies used in this study.</title></caption>
<graphic xlink:href="653866v1_tbls2.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls3" orientation="portrait" position="float">
<label>Supplementary Table 3.</label>
<caption><title>Enzymes used to remove/inactivate RBC receptors and target residues of the enzyme.</title></caption>
<graphic xlink:href="653866v1_tbls3.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
<table-wrap id="tbls4" orientation="portrait" position="float">
<label>Supplementary Table 4.</label>
<caption><title>Primers used for RT-qPCR of <italic>P. falciparum</italic> MSP2, MSP5, MSP4 and controls.</title></caption>
<graphic xlink:href="653866v1_tbls4.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Alan Cowman, Stephen Scally and Jennifer Thompson (WEHI, Melbourne) for provision of PCRCR complex antibodies, Paul Gilson (Burnet Institute, Melb) for EXP2 antibodies, Dr Chris MacRaild (Monash University) for helpful discussion, Dr Sonja FrÃ¶lich (the University of Adelaide) for assistance on quantitative immunofluorescence assays and Adelaide Microscopy for training and use of microscopy instruments. We thank Lifeblood, Australia, for provision of RBCs. DWW was supported by a Hospital Research Foundation (C-MCF-52-2019) and Australian Research Council (FT240100420) Future Fellowship. DWW and JGB by a Hospital Research Foundation Collaborative Grant (S-03-EOI-2021). JGB was supported by the National Health and Medical Research Council of Australia (Research Fellowship and Investigator Grant to JGB, Australian Centre for Research Excellence in Malaria Research). IGH and JC were supported by an Australian Research Council RTP scholarship. The Burnet Institute is supported by the NHMRC for Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support.</p>
</ack>
<sec id="d1e2711" sec-type="additional-information">
<title>Additional information</title>
<sec id="s6">
<title>Author Contributions</title>
<p>Conceived and designed the experiments: DWW, IGH, JC, JGB, DA, MF, RA. Performed the experiments and phylogenetic analysis: IGH, JC, KHL, OR, DA, KRT, NB. Analysed the data: IGH, DWW, JC, KHL, OR, DA, MF. Provided key discussions on PfMSP2 and/or key reagents: RA, MF, DA. Paper writing: DWW, JC, IGH, JGB with critical input from RA, MF, DA, OR, KRT and based on the PhD thesis of IGH.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>MacRaild</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Wycherley</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Kienzle</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Masendycz</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F</given-names></string-name></person-group>., <year>2012</year>. <article-title>Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2</article-title>. <source>Infect Immun</source> <volume>80</volume>, <fpage>4177</fpage>â<lpage>4185</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00665-12</pub-id></mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Murphy</surname>, <given-names>V.J.</given-names></string-name>, <string-name><surname>Sunde</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Waddington</surname>, <given-names>L.J.</given-names></string-name>, <string-name><surname>Schloegel</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Talbo</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Vingas</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Kienzle</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Masciantonio</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Howlett</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Hodder</surname>, <given-names>A.N.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F</given-names></string-name></person-group>., <year>2009</year>. <article-title>Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils</article-title>. <source>Mol Biochem Parasitol</source> <volume>166</volume>, <fpage>159</fpage>â<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.molbiopara.2009.03.012</pub-id></mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alanine</surname>, <given-names>D.G.W.</given-names></string-name>, <string-name><surname>Quinkert</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Kumarasingha</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Mehmood</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Donnellan</surname>, <given-names>F.R.</given-names></string-name>, <string-name><surname>Minkah</surname>, <given-names>N.K.</given-names></string-name>, <string-name><surname>Dadonaite</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Diouf</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Galaway</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Silk</surname>, <given-names>S.E.</given-names></string-name>, <string-name><surname>Jamwal</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Marshall</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Miura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Foquet</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Elias</surname>, <given-names>S.C.</given-names></string-name>, <string-name><surname>LabbÃ©</surname>, <given-names>G.M.</given-names></string-name>, <string-name><surname>Douglas</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Jin</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Payne</surname>, <given-names>R.O.</given-names></string-name>, <string-name><surname>Illingworth</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Pattinson</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Pulido</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Williams</surname>, <given-names>B.G.</given-names></string-name>, <string-name><surname>de Jongh</surname>, <given-names>W.A.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Kappe</surname>, <given-names>S.H.I.</given-names></string-name>, <string-name><surname>Robinson</surname>, <given-names>C. V</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Higgins</surname>, <given-names>M.K.</given-names></string-name>, <string-name><surname>Draper</surname>, <given-names>S.J</given-names></string-name></person-group>., <year>2019</year>. <article-title>Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies</article-title>. <source>Cell</source> <volume>178</volume>, <fpage>216</fpage>â<lpage>228.e21.</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2019.05.025</pub-id></mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S</given-names></string-name></person-group>., <year>2010</year>. <article-title>Recombinant protein vaccines against the asexual blood-stages of Plasmodium falciparum</article-title>. <source>Hum Vaccin</source> <volume>6</volume>, <fpage>39</fpage>â<lpage>53</lpage>. <pub-id pub-id-type="doi">10.4161/hv.6.1.10712</pub-id></mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angage</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Chmielewski</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Maddumage</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Hesping</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Caiazzo</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lai</surname>, <given-names>K.H.</given-names></string-name>, <string-name><surname>Yeoh</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Menassa</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Opi</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Cairns</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Puthalakath</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Kvansakul</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Boddey</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M</given-names></string-name></person-group>., <year>2024</year>. <article-title>A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites</article-title>. <source>Nat Commun</source> <volume>15</volume>, <fpage>7206</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-50770-7</pub-id></mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aurrecoechea</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Brestelli</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Brunk</surname>, <given-names>B.P.</given-names></string-name>, <string-name><surname>Dommer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Fischer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gajria</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Gingle</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Harb</surname>, <given-names>O.S.</given-names></string-name>, <string-name><surname>Heiges</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Innamorato</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Iodice</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kissinger</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Kraemer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Miller</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Nayak</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Pennington</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Pinney</surname>, <given-names>D.F.</given-names></string-name>, <string-name><surname>Roos</surname>, <given-names>D.S.</given-names></string-name>, <string-name><surname>Ross</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Stoeckert</surname>, <given-names>J.C.J.</given-names></string-name>, <string-name><surname>Treatman</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>H</given-names></string-name></person-group>., <year>2009</year>. <article-title>PlasmoDB: a functional genomic database for malaria parasites</article-title>. <source>Nucleic Acids Res</source> <volume>37</volume>, <fpage>D539</fpage>â<lpage>D543</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn814</pub-id></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bannister</surname>, <given-names>L.H.</given-names></string-name>, <string-name><surname>Mitchell</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Butcher</surname>, <given-names>G.A.</given-names></string-name>, <string-name><surname>Gennis</surname>, <given-names>E.D.</given-names></string-name>, <string-name><surname>Cohen</surname>, <given-names>S</given-names></string-name></person-group>., <year>1986</year>. <article-title>Structure and development of the surface coat of erythrocytic merozoites of Plasmodium knowlesi</article-title>. <source>Cell Tissue Res</source> <volume>245</volume>, <fpage>281</fpage>â <lpage>290</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baum</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Maier</surname>, <given-names>A.G.</given-names></string-name>, <string-name><surname>Good</surname>, <given-names>R.T.</given-names></string-name>, <string-name><surname>Simpson</surname>, <given-names>K.M.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F</given-names></string-name></person-group>., <year>2005</year>. <article-title>Invasion by P. falciparum Merozoites Suggests a Hierarchy of Molecular Interactions</article-title>. <source>PLoS Pathog</source> <volume>1</volume>, <fpage>e37</fpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Drew</surname>, <given-names>D.R.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.I.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S</given-names></string-name></person-group>., <year>2016</year>. <article-title>Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria</article-title>. <source>FEMS Microbiol Rev</source> <volume>40</volume>, <fpage>343</fpage>â<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fuw001</pub-id></mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Kurtovic</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>DobaÃ±o</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Opi</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>J.-A.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Good</surname>, <given-names>M.F.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J</given-names></string-name></person-group>., <year>2019</year>. <article-title>Challenges and strategies for developing efficacious and long-lasting malaria vaccines</article-title>. <source>Sci Transl Med</source> <volume>11</volume>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aau1458</pub-id></mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Black</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Barnwell</surname>, <given-names>J.W.</given-names></string-name>, <string-name><surname>Huber</surname>, <given-names>C.S.</given-names></string-name>, <string-name><surname>Galinski</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Coppel</surname>, <given-names>R.L</given-names></string-name></person-group>., <year>2002</year>. <article-title>The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite</article-title>. <source>Mol Biochem Parasitol</source> <volume>120</volume>, <fpage>215</fpage>â<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-6851(01)00458-3</pub-id></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>BÃ¶hme</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Otto</surname>, <given-names>T.D.</given-names></string-name>, <string-name><surname>Cotton</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Steinbiss</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sanders</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Oyola</surname>, <given-names>S.O.</given-names></string-name>, <string-name><surname>Nicot</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gandon</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Patra</surname>, <given-names>K.P.</given-names></string-name>, <string-name><surname>Herd</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bushell</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Modrzynska</surname>, <given-names>K.K.</given-names></string-name>, <string-name><surname>Billker</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Vinetz</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Rivero</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Newbold</surname>, <given-names>C.I.</given-names></string-name>, <string-name><surname>Berriman</surname>, <given-names>M</given-names></string-name></person-group>., <year>2018</year>. <article-title>Complete avian malaria parasite genomes reveal features associated with lineage-specific evolution in birds and mammals</article-title>. <source>Genome Res</source> <volume>28</volume>, <fpage>547</fpage>â<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1101/gr.218123.116</pub-id></mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>J.-A.</given-names></string-name>, <string-name><surname>Hodder</surname>, <given-names>A.N.</given-names></string-name>, <string-name><surname>Coppel</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2014</year>. <article-title>Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum</article-title>. <source>Infect Immun</source> <volume>82</volume>, <fpage>924</fpage>â<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00866-13</pub-id></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Osier</surname>, <given-names>F.H.</given-names></string-name>, <string-name><surname>Aspeling-Jones</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>Y.S.</given-names></string-name>, <string-name><surname>Stubbs</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tetteh</surname>, <given-names>K.K.A.</given-names></string-name>, <string-name><surname>Conway</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>McCarthy</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Muller</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2015</year>. <article-title>Human antibodies fix complement to inhibit plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria</article-title>. <source>Immunity</source> <volume>42</volume>, <fpage>580</fpage>â<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.012</pub-id></mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Chai</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2010a</year>. <article-title>Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites</article-title>. <source>Blood</source> <volume>115</volume>, <fpage>4559</fpage>â <lpage>4568</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-09-243725</pub-id></mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Riglar</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>Tetteh</surname>, <given-names>K.K.A.</given-names></string-name>, <string-name><surname>Conway</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Ralph</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Baum</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2010b</year>. <article-title>Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>107</volume>, <fpage>14378</fpage>â<lpage>14383</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1009198107</pub-id></mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coley</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Gupta</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Murphy</surname>, <given-names>V.J.</given-names></string-name>, <string-name><surname>Bai</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Batchelor</surname>, <given-names>A.H</given-names></string-name></person-group>., <year>2007</year>. <article-title>Structure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory Antibody</article-title>. <source>PLoS Pathog</source> <volume>3</volume>, <fpage>e138</fpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cowman</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Tonkin</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Tham</surname>, <given-names>W.-H.</given-names></string-name>, <string-name><surname>Duraisingh</surname>, <given-names>M.T</given-names></string-name></person-group>., <year>2017</year>. <article-title>The Molecular Basis of Erythrocyte Invasion by Malaria Parasites</article-title>. <source>Cell Host Microbe</source> <volume>22</volume>, <fpage>232</fpage>â<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2017.07.003</pub-id></mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crosnier</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bustamante</surname>, <given-names>L.Y.</given-names></string-name>, <string-name><surname>Bartholdson</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Bei</surname>, <given-names>A.K.</given-names></string-name>, <string-name><surname>Theron</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Uchikawa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mboup</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ndir</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Kwiatkowski</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Duraisingh</surname>, <given-names>M.T.</given-names></string-name>, <string-name><surname>Rayner</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.J</given-names></string-name></person-group>., <year>2011</year>. <article-title>Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum</article-title>. <source>Nature</source> <volume>480</volume>, <fpage>534</fpage>â<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1038/nature10606</pub-id></mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Das</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hertrich</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Perrin</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Withers-Martinez</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>C.R.</given-names></string-name>, <string-name><surname>Jones</surname>, <given-names>M.L.</given-names></string-name>, <string-name><surname>Watermeyer</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Fobes</surname>, <given-names>E.T.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>S.R.</given-names></string-name>, <string-name><surname>Saibil</surname>, <given-names>H.R.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Treeck</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Epp</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Blackman</surname>, <given-names>M.J</given-names></string-name></person-group>., <year>2015</year>. <article-title>Processing of Plasmodium falciparum Merozoite Surface Protein MSP1 Activates a Spectrin-Binding Function Enabling Parasite Egress from RBCs</article-title>. <source>Cell Host Microbe</source> <volume>18</volume>, <fpage>433</fpage>â<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2015.09.007</pub-id></mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Datoo</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Dicko</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tinto</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>OuÃ©draogo</surname>, <given-names>J.B.</given-names></string-name>, <string-name><surname>Hamaluba</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Olotu</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Beaumont</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ramos Lopez</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Natama</surname>, <given-names>H.M.</given-names></string-name>, <string-name><surname>Weston</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chemba</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Compaore</surname>, <given-names>Y.D.</given-names></string-name>, <string-name><surname>Issiaka</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Salou</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Some</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Omenda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lawrie</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bejon</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Rao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chandramohan</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Roberts</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Bharati</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Stockdale</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Gairola</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Greenwood</surname>, <given-names>B.M.</given-names></string-name>, <string-name><surname>Ewer</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Bradley</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kulkarni</surname>, <given-names>P.S.</given-names></string-name>, <string-name><surname>Shaligram</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A.V.S.</given-names></string-name>, <string-name><surname>Mahamar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sanogo</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sidibe</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Diarra</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Samassekou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Attaher</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Tapily</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Diallo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dicko</surname>, <given-names>O.M.</given-names></string-name>, <string-name><surname>Kaya</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Maguiraga</surname>, <given-names>S.O.</given-names></string-name>, <string-name><surname>Sankare</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yalcouye</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Diarra</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Niambele</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Thera</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Sagara</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Sylla</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dolo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Misidai</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Simando</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Msami</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Juma</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Gutapaka</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Paul</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Mswata</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sasamalo</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Johaness</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sultan</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Alexander</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kimaro</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Lwanga</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mtungwe</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Khamis</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Rugarabam</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Kalinga</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Mohammed</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kamange</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Msangi</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Mwaijande</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Mtaka</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Mhapa</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mlaganile</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Mbaga</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yerbanga</surname>, <given-names>R.S.</given-names></string-name>, <string-name><surname>Samtouma</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Sienou</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Kabre</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Ouedraogo</surname>, <given-names>W.J.M.</given-names></string-name>, <string-name><surname>Yarbanga</surname>, <given-names>G.A.B.</given-names></string-name>, <string-name><surname>Zongo</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Savadogo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sanon</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Compaore</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kere</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Yoni</surname>, <given-names>F.L.</given-names></string-name>, <string-name><surname>Sanre</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Ouattara</surname>, <given-names>S.B.</given-names></string-name>, <string-name><surname>Provstgaard-Morys</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Woods</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Snow</surname>, <given-names>R.W.</given-names></string-name>, <string-name><surname>Amek</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ngetsa</surname>, <given-names>C.J.</given-names></string-name>, <string-name><surname>Ochola-Oyier</surname>, <given-names>L.I.</given-names></string-name>, <string-name><surname>Musyoki</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Munene</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mumba</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Adetifa</surname>, <given-names>U.J.</given-names></string-name>, <string-name><surname>Muiruri</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Mwawaka</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Mwaganyuma</surname>, <given-names>M.H.</given-names></string-name>, <string-name><surname>Ndichu</surname>, <given-names>M.N.</given-names></string-name>, <string-name><surname>Weya</surname>, <given-names>J.O.</given-names></string-name>, <string-name><surname>Njogu</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Grant</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Webster</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lakhkar</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ido</surname>, <given-names>N.F.A.</given-names></string-name>, <string-name><surname>Traore</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Tahita</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Bonko</surname>, <given-names>M. dit A.</given-names></string-name>, <string-name><surname>Rouamba</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ouedraogo</surname>, <given-names>D.F.</given-names></string-name>, <string-name><surname>Soma</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Millogo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ouedraogo</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Sorgho</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Konate</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Valea</surname>, <given-names>I.</given-names></string-name></person-group>, <year>2024</year>. <article-title>Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial</article-title>. <source>The Lancet</source> <volume>403</volume>, <fpage>533</fpage>â<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(23)02511-4</pub-id></mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Schlesinger</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Drenkow</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zaleski</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jha</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Batut</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chaisson</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gingeras</surname>, <given-names>T.R.</given-names></string-name></person-group>, <year>2013</year>. <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source> <volume>29</volume>, <fpage>15</fpage>â<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id></mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Douglas</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Williams</surname>, <given-names>A.R.</given-names></string-name>, <string-name><surname>Illingworth</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Kamuyu</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Biswas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Goodman</surname>, <given-names>A.L.</given-names></string-name>, <string-name><surname>Wyllie</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Crosnier</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Miura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Osier</surname>, <given-names>F.H.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Turner</surname>, <given-names>A. V.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A.V.S.</given-names></string-name>, <string-name><surname>Draper</surname>, <given-names>S.J.</given-names></string-name></person-group>, <year>2011</year>. <article-title>The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody</article-title>. <source>Nat Commun</source> <volume>2</volume>, <fpage>601</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1615</pub-id></mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duraisingh</surname>, <given-names>M.T.</given-names></string-name>, <string-name><surname>Maier</surname>, <given-names>A.G.</given-names></string-name>, <string-name><surname>Triglia</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F</given-names></string-name></person-group>., <year>2003</year>. <article-title>Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>100</volume>, <fpage>4796</fpage>â<lpage>4801</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0730883100</pub-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenhaber</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Bork</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Eisenhaber</surname>, <given-names>F</given-names></string-name></person-group>., <year>1999</year>. <article-title>Prediction of potential GPI-modification sites in proprotein sequences</article-title>. <source>J Mol Biol</source> <volume>292</volume>, <fpage>741</fpage>â<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1999.3069</pub-id></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Escalante</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Cepeda</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>Pacheco</surname>, <given-names>M.A</given-names></string-name></person-group>., <year>2022</year>. <article-title>Why Plasmodium vivax and Plasmodium falciparum are so different? A tale of two clades and their species diversities</article-title>. <source>Malar J</source> <volume>21</volume>, <fpage>139</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-022-04130-9</pub-id></mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Cross</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>J.-A.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Osier</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Stanisic</surname>, <given-names>D.I.</given-names></string-name>, <string-name><surname>Mueller</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>McCarthy</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2018</year>. <article-title>Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains</article-title>. <source>J Infect Dis</source> <volume>218</volume>, <fpage>35</fpage>â<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiy170</pub-id></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferreira</surname>, <given-names>E. dâAvila</given-names></string-name>, <string-name><surname>Alexandre</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Salinas</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>de Siqueira</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Benzecry</surname>, <given-names>S.G.</given-names></string-name>, <string-name><surname>de Lacerda</surname>, <given-names>M.V.G.</given-names></string-name>, <string-name><surname>Monteiro</surname>, <given-names>W.M.</given-names></string-name></person-group>, <year>2015</year>. <article-title>Association between anthropometry-based nutritional status and malaria: a systematic review of observational studies</article-title>. <source>Malaria J</source> <volume>14</volume>, <fpage>346</fpage>. <pub-id pub-id-type="doi">10.1186/s12936-015-0870-5</pub-id></mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fowkes</surname>, <given-names>F.J.I.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Simpson</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2010</year>. <article-title>The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis</article-title>. <source>PLoS Med</source> <volume>7</volume>, <fpage>e1000218</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1000218</pub-id></mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genton</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Al-Yaman</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Betuela</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Saul</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Baea</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mellombo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Taraika</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>G. V.</given-names></string-name>, <string-name><surname>Pye</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Irving</surname>, <given-names>D.O.</given-names></string-name>, <string-name><surname>Felger</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Beck</surname>, <given-names>H.-P.P.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>T.A.</given-names></string-name>, <string-name><surname>Alpers</surname>, <given-names>M.P.</given-names></string-name></person-group>, <year>2003</year>. <article-title>Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children</article-title>. <source>Vaccine</source> <volume>22</volume>, <fpage>30</fpage>â<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(03)00536-X</pub-id></mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genton</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Betuela</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Felger</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Al-Yaman</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Saul</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Rare</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Baisor</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lorry</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Brown</surname>, <given-names>G. V</given-names></string-name>, <string-name><surname>Pye</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Irving</surname>, <given-names>D.O.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>T.A.</given-names></string-name>, <string-name><surname>Beck</surname>, <given-names>H.-P.</given-names></string-name>, <string-name><surname>Alpers</surname>, <given-names>M.P</given-names></string-name></person-group>., <year>2002</year>. <article-title>A Recombinant Blood-Stage Malaria Vaccine Reduces Plasmodium falciparum Density and Exerts Selective Pressure on Parasite Populations in a Phase 1-2b Trial in Papua New Guinea</article-title>. <source>J Infect Dis</source> <volume>185</volume>, <fpage>820</fpage>â<lpage>827</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Nebl</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Vukcevic</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Moritz</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Sargeant</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Speed</surname>, <given-names>T.P.</given-names></string-name>, <string-name><surname>Schofield</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S</given-names></string-name></person-group>., <year>2006</year>. <article-title>Identification and Stoichiometry of Glycosylphosphatidylinositol-anchored Membrane Proteins of the Human Malaria Parasite <italic>Plasmodium falciparum</italic></article-title>. <source>Molecular &amp; Cellular Proteomics</source> <volume>5</volume>, <fpage>1286</fpage>â<lpage>1299</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M600035-MCP200</pub-id></mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Griffiths</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Dolezal</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Cao</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Nilsson</surname>, <given-names>S.K.</given-names></string-name>, <string-name><surname>See</surname>, <given-names>H.B.</given-names></string-name>, <string-name><surname>Pfleger</surname>, <given-names>K.D.G.</given-names></string-name>, <string-name><surname>Roche</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gorry</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Pow</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Viduka</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lim</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>B.G.C.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>D.H.C.</given-names></string-name>, <string-name><surname>Murray-Rust</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kvansakul</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Perugini</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Dogovski</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Doerflinger</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Parisi</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Casey</surname>, <given-names>J.L.</given-names></string-name>, <string-name><surname>Nuttall</surname>, <given-names>S.D.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M</given-names></string-name></person-group>., <year>2016</year><article-title>. i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4</article-title>. <source>J Biol Chem</source> <volume>291</volume>, <fpage>12641</fpage>â<lpage>12657</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.721050</pub-id></mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Griffiths</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Habiel</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Jaffar</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Binder</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Darby</surname>, <given-names>W.G.</given-names></string-name>, <string-name><surname>Hosking</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Skerra</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Westall</surname>, <given-names>G.P.</given-names></string-name>, <string-name><surname>Hogaboam</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Foley</surname>, <given-names>M</given-names></string-name></person-group>., <year>2018</year>. <article-title>Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis</article-title>. <source>Sci Rep</source> <volume>8</volume>, <fpage>3212</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-20811-5</pub-id></mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jumper</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Evans</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Pritzel</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Green</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Figurnov</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ronneberger</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Tunyasuvunakool</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Bates</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Å½Ã­dek</surname>, <given-names>A</given-names></string-name>., <string-name><surname>Potapenko</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bridgland</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Meyer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kohl</surname>, <given-names>S.A.A.</given-names></string-name>, <string-name><surname>Ballard</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Cowie</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Romera-Paredes</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Nikolov</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jain</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Adler</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Back</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Petersen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Reiman</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Clancy</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Zielinski</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Steinegger</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Pacholska</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Berghammer</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Bodenstein</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Silver</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Vinyals</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Senior</surname>, <given-names>A.W.</given-names></string-name>, <string-name><surname>Kavukcuoglu</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Kohli</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hassabis</surname>, <given-names>D.</given-names></string-name></person-group>, <year>2021</year>. <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>. <source>Nature</source> <volume>596</volume>, <fpage>583</fpage>â<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id></mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kals</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Kals</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lees</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Introini</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Kemp</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Silvester</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>C.R.</given-names></string-name>, <string-name><surname>Umrekar</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kotar</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cicuta</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Rayner</surname>, <given-names>J.C</given-names></string-name></person-group>., <year>2024</year>. <article-title>Application of optical tweezer technology reveals that PfEBA and PfRH ligands, not PfMSP1, play a central role in Plasmodium falciparum merozoite-erythrocyte attachment</article-title>. <source>PLoS Pathog</source> <volume>20</volume>, <fpage>e1012041</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1012041</pub-id></mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kocken</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>van der Wel</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Dubbeld</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Narum</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>van de Rijke</surname>, <given-names>F.M.</given-names></string-name>, <string-name><surname>van Gemert</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>van der Linde</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Bannister</surname>, <given-names>L.H.</given-names></string-name>, <string-name><surname>Janse</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Waters</surname>, <given-names>A.P.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>A.W.</given-names></string-name></person-group>, <year>1998</year>. <article-title>Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization</article-title>. <source>J Biol Chem</source> <volume>273</volume>, <fpage>15119</fpage>â<lpage>15124</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.24.15119</pub-id></mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamarque</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Besteiro</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Papoin</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Roques</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Vulliez-Le Normand</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Morlon-Guyot</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Dubremetz</surname>, <given-names>J.-F.</given-names></string-name>, <string-name><surname>Fauquenoy</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tomavo</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Faber</surname>, <given-names>B.W.</given-names></string-name>, <string-name><surname>Kocken</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>A.W.</given-names></string-name>, <string-name><surname>Boulanger</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Bentley</surname>, <given-names>G.A.</given-names></string-name>, <string-name><surname>Lebrun</surname>, <given-names>M.</given-names></string-name></person-group>, <year>2011</year>. <article-title>The RON2-AMA1 Interaction is a Critical Step in Moving Junction-Dependent Invasion by Apicomplexan Parasites</article-title>. <source>PLoS Pathog</source> <volume>7</volume>, <fpage>e1001276</fpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Oo</surname>, <given-names>T.H.</given-names></string-name>, <string-name><surname>Daly</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Bergman</surname>, <given-names>L.W.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>S.-C.</given-names></string-name>, <string-name><surname>Chishti</surname>, <given-names>A.H.</given-names></string-name>, <string-name><surname>Oh</surname>, <given-names>S.S</given-names></string-name></person-group>., <year>2004</year>. <article-title>A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3</article-title>. <source>J Biol Chem</source> <volume>279</volume>, <fpage>5765</fpage>â<lpage>5771</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M308716200</pub-id></mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>L.-Q</given-names></string-name></person-group>., <year>2024</year>. <article-title>Effects of intrinsically disordered regions in gp120 underlying HIV neutralization phenotypes</article-title>. <source>Biochem Biophys Res Commun</source> <volume>709</volume>, <fpage>149830</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2024.149830</pub-id></mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Smyth</surname>, <given-names>G.K.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>W</given-names></string-name></person-group>., <year>2014</year>. <article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title>. <source>Bioinformatics</source> <volume>30</volume>, <fpage>923</fpage>â<lpage>930</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id></mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liffner</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>FrÃ¶lich</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Heinemann</surname>, <given-names>G.K.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Ralph</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Dixon</surname>, <given-names>M.W.A.</given-names></string-name>, <string-name><surname>Gilberger</surname>, <given-names>T.W.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>D.W</given-names></string-name></person-group>., <year>2020</year>. <article-title>PfCERLI1 is a conserved rhoptry associated protein essential for Plasmodium falciparum merozoite invasion of erythrocytes</article-title>. <source>Nat Commun</source> <volume>11</volume>. <pub-id pub-id-type="doi">10.1038/s41467-020-15127-w</pub-id></mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livak</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Schmittgen</surname>, <given-names>T.D</given-names></string-name></person-group>., <year>2001</year>. <article-title>Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2âÎÎCT Method</article-title>. <source>Methods</source> <volume>25</volume>, <fpage>402</fpage>â<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname>, <given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>S</given-names></string-name></person-group>., <year>2014</year>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source> <volume>15</volume>, <fpage>550</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>MacRaild</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S.</given-names></string-name>, <string-name><surname>Zhuang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X</given-names></string-name></person-group>., <year>2019</year>. <article-title>Interaction of merozoite surface protein 2 with lipid membranes</article-title>. <source>FEBS Lett</source> <volume>593</volume>, <fpage>288</fpage>â<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.13320</pub-id></mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>MacRaild</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Pedersen</surname>, <given-names>M.Ã.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S</given-names></string-name></person-group>., <year>2012</year>. <article-title>Lipid interactions of the malaria antigen merozoite surface protein 2</article-title>. <source>Biochim Biophys Acta</source> <volume>1818</volume>, <fpage>2572</fpage>â<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2012.06.015</pub-id></mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>MacRaild</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Zachrdla</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Andrew</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Krishnarjuna</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>NovÃ¡Äek</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Å½Ã­dek</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>SklenÃ¡Å</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S.</given-names></string-name></person-group>, <year>2015</year>. <article-title>Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2</article-title>. <source>PLoS One</source> <volume>10</volume>, <fpage>e0119899</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0119899</pub-id></mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McCarthy</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Marjason</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Elliott</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Fahey</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Bang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Malkin</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Tierney</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Aked-Hurditch</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Adda</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cross</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Druilhe</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F</given-names></string-name></person-group>., <year>2011</year>. <article-title>A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with montanideÂ® ISA 720</article-title>. <source>PLoS One</source> <volume>6</volume>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024413</pub-id></mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ocampo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Urquiza</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>GuzmÃ¡n</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Rodriguez</surname>, <given-names>L.E.</given-names></string-name>, <string-name><surname>Suarez</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Curtidor</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Rosas</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Diaz</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Patarroyo</surname>, <given-names>M.E</given-names></string-name></person-group>., <year>2003</year>. <article-title>Two MSA 2 peptides that bind to human red blood cells are relevant to Plasmodium falciparum merozoite invasion</article-title>. <source>The Journal of Peptide Research</source> <volume>55</volume>, <fpage>216</fpage>â<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1034/j.1399-3011.2000.00174.x</pub-id></mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Orlandi</surname>, <given-names>P.A.</given-names></string-name>, <string-name><surname>Klotz</surname>, <given-names>F.W.</given-names></string-name>, <string-name><surname>Haynes</surname>, <given-names>J.D</given-names></string-name></person-group>., <year>1992</year>. <article-title>A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac (alpha 2-3) Gal-sequences of glycophorin A</article-title>. <source>J Cell Biol</source> <volume>116</volume>, <fpage>901</fpage>â<lpage>909</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Osier</surname>, <given-names>F.H.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>McCallum</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Jaworowski</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2014</year>. <article-title>Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria</article-title>. <source>BMC Med</source> <volume>12</volume>, <fpage>108</fpage>. <pub-id pub-id-type="doi">10.1186/1741-7015-12-108</pub-id></mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Osier</surname>, <given-names>F.H.A.</given-names></string-name>, <string-name><surname>Murungi</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Fegan</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Tuju</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Tetteh</surname>, <given-names>K.K.</given-names></string-name>, <string-name><surname>Bull</surname>, <given-names>P.C.</given-names></string-name>, <string-name><surname>Conway</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K</given-names></string-name></person-group>., <year>2010</year>. <article-title>Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria</article-title>. <source>Parasite Immunol</source> <volume>32</volume>, <fpage>193</fpage>â<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3024.2009.01178.x</pub-id></mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Tarleton</surname>, <given-names>R</given-names></string-name></person-group>., <year>2015</year>. <article-title>EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens</article-title>. <source>Microb Genom</source> <volume>1</volume>. <pub-id pub-id-type="doi">10.1099/mgen.0.000033</pub-id></mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Persson</surname>, <given-names>K.E.M.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.</given-names></string-name>, <string-name><surname>McCallum</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Gicheru</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Lopaticki</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2013</year>. <article-title>Erythrocyte-Binding Antigens of Plasmodium falciparum Are Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity</article-title>. <source>The Journal of Immunology</source> <volume>191</volume>, <fpage>785</fpage>â<lpage>794</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1300444</pub-id></mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Persson</surname>, <given-names>K.E.M.</given-names></string-name>, <string-name><surname>McCallum</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lister</surname>, <given-names>N.A.</given-names></string-name>, <string-name><surname>Stubbs</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Marsh</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2008</year>. <article-title>Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies</article-title>. <source>J Clin Invest</source> <volume>118</volume>, <fpage>342</fpage>â<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1172/JCI32138</pub-id></mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Boyle</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>White</surname>, <given-names>M.T.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Feng</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Weaver</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Opi</surname>, <given-names>D.H.</given-names></string-name>, <string-name><surname>Persson</surname>, <given-names>K.E.M.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Siba</surname>, <given-names>P.M.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.</given-names></string-name>, <string-name><surname>Takashima</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Tsuboi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Mueller</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2019</year>. <article-title>Targets of complement-fixing antibodies in protective immunity against malaria in children</article-title>. <source>Nat Commun</source> <volume>10</volume>, <fpage>610</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-08528-z</pub-id></mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>RessurreiÃ§Ã£o</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Nofal</surname>, <given-names>S.D.</given-names></string-name>, <string-name><surname>Flueck</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Moon</surname>, <given-names>R.W.</given-names></string-name>, <string-name><surname>Baker</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>van Ooij</surname>, <given-names>C.</given-names></string-name></person-group>, <year>2020</year>. <article-title>Use of a highly specific kinase inhibitor for rapid, simple and precise synchronization of Plasmodium falciparum and Plasmodium knowlesi asexual blood-stage parasites</article-title>. <source>PLoS One</source> <volume>15</volume>, <fpage>e0235798</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0235798</pub-id></mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Arumugam</surname>, <given-names>T.U.</given-names></string-name>, <string-name><surname>Reiling</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Healer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hodder</surname>, <given-names>A.N.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.</given-names></string-name>, <string-name><surname>Cross</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Takeo</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Uboldi</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>J.K.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Coppel</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Siba</surname>, <given-names>P.M.</given-names></string-name>, <string-name><surname>King</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Torii</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chitnis</surname>, <given-names>C.E.</given-names></string-name>, <string-name><surname>Narum</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>Mueller</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Tsuboi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2013</year>. <article-title>Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development</article-title>. <source>The Journal of Immunology</source> <volume>191</volume>, <fpage>795 LP</fpage> â <lpage>809</lpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>RTSS Clinical Trials Partnership</collab></person-group>, <year>2015</year>. <article-title>Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial</article-title>. <source>Lancet</source> <volume>386</volume>, <fpage>31</fpage>â<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60721-8</pub-id></mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sagara</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Dicko</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ellis</surname>, <given-names>R.D.</given-names></string-name>, <string-name><surname>Fay</surname>, <given-names>M.P.</given-names></string-name>, <string-name><surname>Diawara</surname>, <given-names>S.I.</given-names></string-name>, <string-name><surname>Assadou</surname>, <given-names>M.H.</given-names></string-name>, <string-name><surname>Sissoko</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Kone</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Diallo</surname>, <given-names>A.I.</given-names></string-name>, <string-name><surname>Saye</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Guindo</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Kante</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Niambele</surname>, <given-names>M.B.</given-names></string-name>, <string-name><surname>Miura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mullen</surname>, <given-names>G.E.D.</given-names></string-name>, <string-name><surname>Pierce</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>L.B.</given-names></string-name>, <string-name><surname>Dolo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Diallo</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Doumbo</surname>, <given-names>O.K.</given-names></string-name>, <string-name><surname>Miller</surname>, <given-names>L.H.</given-names></string-name>, <string-name><surname>Saul</surname>, <given-names>A</given-names></string-name></person-group>., <year>2009</year>. <article-title>A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali</article-title>. <source>Vaccine</source> <volume>27</volume>, <fpage>3090</fpage>â<lpage>3098</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.03.014</pub-id></mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salanti</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Staalsoe</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Lavstsen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Jensen</surname>, <given-names>A.T.R.</given-names></string-name>, <string-name><surname>Sowa</surname>, <given-names>M.P.K.</given-names></string-name>, <string-name><surname>Arnot</surname>, <given-names>D.E.</given-names></string-name>, <string-name><surname>Hviid</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Theander</surname>, <given-names>T.G.</given-names></string-name></person-group>, <year>2003</year>. <article-title>Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria</article-title>. <source>Mol Microbiol</source> <volume>49</volume>, <fpage>179</fpage>â<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03570.x</pub-id></mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanders</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Kats</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Drew</surname>, <given-names>D.R.</given-names></string-name>, <string-name><surname>OâDonnell</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>OâNeill</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Maier</surname>, <given-names>A.G.</given-names></string-name>, <string-name><surname>Coppel</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S</given-names></string-name></person-group>., <year>2006</year>. <article-title>A Set of Glycosylphosphatidyl Inositol-Anchored Membrane Proteins of Plasmodium falciparum Is Refractory to Genetic Deletion</article-title>. <source>Infect Immun</source> <volume>74</volume>, <fpage>4330</fpage>â<lpage>4338</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00054-06</pub-id></mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scally</surname>, <given-names>S.W.</given-names></string-name>, <string-name><surname>Triglia</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Evelyn</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Seager</surname>, <given-names>B.A.</given-names></string-name>, <string-name><surname>Pasternak</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lim</surname>, <given-names>P.S.</given-names></string-name>, <string-name><surname>Healer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Geoghegan</surname>, <given-names>N.D.</given-names></string-name>, <string-name><surname>Adair</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tham</surname>, <given-names>W.-H.</given-names></string-name>, <string-name><surname>Dagley</surname>, <given-names>L.F.</given-names></string-name>, <string-name><surname>Rogers</surname>, <given-names>K.L.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F</given-names></string-name></person-group>., <year>2022</year>. <article-title>PCRCR complex is essential for invasion of human erythrocytes by Plasmodium falciparum</article-title>. <source>Nat Microbiol</source> <volume>7</volume>, <fpage>2039</fpage>â<lpage>2053</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-022-01261-2</pub-id></mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheehy</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Duncan</surname>, <given-names>C.J.A.</given-names></string-name>, <string-name><surname>Elias</surname>, <given-names>S.C.</given-names></string-name>, <string-name><surname>Choudhary</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Biswas</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Halstead</surname>, <given-names>F.D.</given-names></string-name>, <string-name><surname>Collins</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Edwards</surname>, <given-names>N.J.</given-names></string-name>, <string-name><surname>Douglas</surname>, <given-names>A.D.</given-names></string-name>, <string-name><surname>Anagnostou</surname>, <given-names>N.A.</given-names></string-name>, <string-name><surname>Ewer</surname>, <given-names>K.J.</given-names></string-name>, <string-name><surname>Havelock</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Mahungu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Bliss</surname>, <given-names>C.M.</given-names></string-name>, <string-name><surname>Miura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Poulton</surname>, <given-names>I.D.</given-names></string-name>, <string-name><surname>Lillie</surname>, <given-names>P.J.</given-names></string-name>, <string-name><surname>Antrobus</surname>, <given-names>R.D.</given-names></string-name>, <string-name><surname>Berrie</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Moyle</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gantlett</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Colloca</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Cortese</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Sinden</surname>, <given-names>R.E.</given-names></string-name>, <string-name><surname>Gilbert</surname>, <given-names>S.C.</given-names></string-name>, <string-name><surname>Lawrie</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Doherty</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Faust</surname>, <given-names>S.N.</given-names></string-name>, <string-name><surname>Nicosia</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hill</surname>, <given-names>A.V.S.</given-names></string-name>, <string-name><surname>Draper</surname>, <given-names>S.J</given-names></string-name></person-group>., <year>2012</year>. <article-title>ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans</article-title>. <source>Mol Ther</source> <volume>20</volume>, <fpage>2355</fpage>â<lpage>2368</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2012.223</pub-id></mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smythe</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Coppel</surname>, <given-names>R.L.</given-names></string-name>, <string-name><surname>Day</surname>, <given-names>K.P.</given-names></string-name>, <string-name><surname>Martin</surname>, <given-names>R.K.</given-names></string-name>, <string-name><surname>Oduola</surname>, <given-names>A.M.</given-names></string-name>, <string-name><surname>Kemp</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F</given-names></string-name></person-group>., <year>1991</year>. <article-title>Structural diversity in the Plasmodium falciparum merozoite surface antigen 2</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>88</volume>, <fpage>1751 LP</fpage> â <lpage>1755</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.88.5.1751</pub-id></mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srinivasan</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Beatty</surname>, <given-names>W.L.</given-names></string-name>, <string-name><surname>Diouf</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Herrera</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ambroggio</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Moch</surname>, <given-names>J.K.</given-names></string-name>, <string-name><surname>Tyler</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Narum</surname>, <given-names>D.L.</given-names></string-name>, <string-name><surname>Pierce</surname>, <given-names>S.K.</given-names></string-name>, <string-name><surname>Boothroyd</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Haynes</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Miller</surname>, <given-names>L.H</given-names></string-name></person-group>., <year>2011</year>. <article-title>Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion</article-title>. <source>Proceedings of the National Academy of Sciences</source> <volume>108</volume>, 13275â13280. <pub-id pub-id-type="doi">10.1073/pnas.1110303108</pub-id></mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stanisic</surname>, <given-names>D.I.</given-names></string-name>, <string-name><surname>Richards</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>McCallum</surname>, <given-names>F.J.</given-names></string-name>, <string-name><surname>Michon</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>King</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>Schoepflin</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Murphy</surname>, <given-names>V.J.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Mueller</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G</given-names></string-name></person-group>., <year>2009</year>. <article-title>Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness</article-title>. <source>Infect Immun</source> <volume>77</volume>, <fpage>1165</fpage>â<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01129-08</pub-id></mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stejskal</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Kalemera</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Lewis</surname>, <given-names>C.B.</given-names></string-name>, <string-name><surname>Palor</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Walker</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Daviter</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Lees</surname>, <given-names>W.D.</given-names></string-name>, <string-name><surname>Moss</surname>, <given-names>D.S.</given-names></string-name>, <string-name><surname>Kremyda-Vlachou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kozlakidis</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Gallo</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Bailey</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Rosenberg</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Illingworth</surname>, <given-names>C.J.R.</given-names></string-name>, <string-name><surname>Shepherd</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Grove</surname>, <given-names>J.</given-names></string-name></person-group>, <year>2022</year>. <article-title>An entropic safety catch controls hepatitis C virus entry and antibody resistance</article-title>. <source>eLife</source> <volume>11</volume>. <pub-id pub-id-type="doi">10.7554/eLife.71854</pub-id></mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tamura</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Stecher</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Kumar</surname>, <given-names>S</given-names></string-name></person-group>., <year>2021</year>. <article-title>MEGA11: Molecular Evolutionary Genetics Analysis Version 11</article-title>. <source>Mol Biol Evol</source> <volume>38</volume>, <fpage>3022</fpage>â<lpage>3027</lpage>. <pub-id pub-id-type="doi">10.1093/molbev/msab120</pub-id></mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname>, <given-names>H.M.</given-names></string-name>, <string-name><surname>McRobert</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Grainger</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sicard</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Dluzewski</surname>, <given-names>A.R.</given-names></string-name>, <string-name><surname>Hopp</surname>, <given-names>C.S.</given-names></string-name>, <string-name><surname>Holder</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Baker</surname>, <given-names>D.A</given-names></string-name></person-group>., <year>2010</year>. <article-title>The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony</article-title>. <source>Eukaryot Cell</source> <volume>9</volume>, <fpage>37</fpage>â<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1128/EC.00186-09</pub-id></mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thera</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Doumbo</surname>, <given-names>O.K.</given-names></string-name>, <string-name><surname>Coulibaly</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Laurens</surname>, <given-names>M.B.</given-names></string-name>, <string-name><surname>Ouattara</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kone</surname>, <given-names>A.K.</given-names></string-name>, <string-name><surname>Guindo</surname>, <given-names>A.B.</given-names></string-name>, <string-name><surname>Traore</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Traore</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Kouriba</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Diallo</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Diarra</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Daou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Dolo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tolo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Sissoko</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Niangaly</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sissoko</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Takala-Harrison</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lyke</surname>, <given-names>K.E.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Blackwelder</surname>, <given-names>W.C.</given-names></string-name>, <string-name><surname>Godeaux</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Vekemans</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Dubois</surname>, <given-names>M.-C.</given-names></string-name>, <string-name><surname>Ballou</surname>, <given-names>W.R.</given-names></string-name>, <string-name><surname>Cohen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Dube</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Soisson</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Diggs</surname>, <given-names>C.L.</given-names></string-name>, <string-name><surname>House</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lanar</surname>, <given-names>D.E.</given-names></string-name>, <string-name><surname>Dutta</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Heppner</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Plowe</surname>, <given-names>C. V</given-names></string-name></person-group>., <year>2011</year>. <article-title>A Field Trial to Assess a Blood-Stage Malaria Vaccine</article-title>. <source>New England Journal of Medicine</source> <volume>365</volume>, <fpage>1004</fpage>â<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1008115</pub-id></mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiss</surname>, <given-names>G.E.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>Taechalertpaisarn</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Tham</surname>, <given-names>W.-H.H.</given-names></string-name>, <string-name><surname>de Jong</surname>, <given-names>N.W.M.M.</given-names></string-name>, <string-name><surname>Harvey</surname>, <given-names>K.L.</given-names></string-name>, <string-name><surname>Fowkes</surname>, <given-names>F.J.I.I.</given-names></string-name>, <string-name><surname>Barlow</surname>, <given-names>P.N.</given-names></string-name>, <string-name><surname>Rayner</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Wright</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Cowman</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S.</given-names></string-name></person-group>, <year>2015</year>. <article-title>Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes</article-title>. <source>PLoS Pathog</source> <volume>11</volume>, <fpage>284</fpage>â<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004670</pub-id></mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname>, <given-names>H.</given-names></string-name></person-group>, <year>2016</year>.<source>ggplot2: Elegant Graphics for Data Analysis</source>. <publisher-name>Springer-Verlag</publisher-name> <publisher-loc>New York</publisher-loc>.</mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname>, <given-names>D.W.</given-names></string-name>, <string-name><surname>Goodman</surname>, <given-names>C.D.</given-names></string-name>, <string-name><surname>Sleebs</surname>, <given-names>B.E.</given-names></string-name>, <string-name><surname>Weiss</surname>, <given-names>G.E.</given-names></string-name>, <string-name><surname>de Jong</surname>, <given-names>N.W.M.</given-names></string-name>, <string-name><surname>Angrisano</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Langer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Baum</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Crabb</surname>, <given-names>B.S.</given-names></string-name>, <string-name><surname>Gilson</surname>, <given-names>P.R.</given-names></string-name>, <string-name><surname>McFadden</surname>, <given-names>G.I.</given-names></string-name>, <string-name><surname>Beeson</surname>, <given-names>J.G.</given-names></string-name></person-group>, <year>2015</year>. <article-title>Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum</article-title>. <source>BMC Biol</source> <volume>13</volume>, <fpage>52</fpage>. <pub-id pub-id-type="doi">10.1186/s12915-015-0162-0</pub-id></mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>, <year>2024</year>. <article-title>World malaria report 2024: addressing inequity in the global malaria response. World Health Organization</article-title>, <source>Geneva</source>.</mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>MacRaild</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Low</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Jackson</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S</given-names></string-name></person-group>., <year>2010</year>. <article-title>Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2)</article-title>. <source>Biochimie</source> <volume>92</volume>, <fpage>1287</fpage>â<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2010.06.001</pub-id></mixed-citation></ref>
<ref id="c77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zerebinski</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Margerie</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>N.S.</given-names></string-name>, <string-name><surname>Moll</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ritvos</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Jahnmatz</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ahlborg</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ngasala</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Rooth</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>SjÃ¶berg</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Sundling</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Yman</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>FÃ¤rnert</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Plaza</surname>, <given-names>D.F</given-names></string-name></person-group>., <year>2024</year>. <article-title>Naturally acquired IgG responses to Plasmodium falciparum do not target the conserved termini of the malaria vaccine candidate Merozoite Surface Protein 2</article-title>. <source>Front Immunol</source> <volume>15</volume>, <fpage>1501700</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1501700</pub-id></mixed-citation></ref>
<ref id="c78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Low</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Tu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S</given-names></string-name></person-group>., <year>2012</year>. <article-title>Role of the helical structure of the N-terminal region of plasmodium falciparum merozoite surface protein 2 in fibril formation and membrane interaction</article-title>. <source>Biochemistry</source> <volume>51</volume>, <fpage>1380</fpage>â<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1021/bi201880s</pub-id></mixed-citation></ref>
<ref id="c79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Perugini</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Yao</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Adda</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Murphy</surname>, <given-names>V.J.</given-names></string-name>, <string-name><surname>Low</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Anders</surname>, <given-names>R.F.</given-names></string-name>, <string-name><surname>Norton</surname>, <given-names>R.S</given-names></string-name></person-group>., <year>2008</year>. <article-title>Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2</article-title>. <source>J Mol Biol</source> <volume>379</volume>, <fpage>105</fpage>â<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2008.03.039</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107603.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Krzych</surname>
<given-names>Urszula</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Walter Reed Army Institute of Research</institution>
</institution-wrap>
<city>Silver Spring</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> work offers a fresh perspective central to merozoite surface biology and potential implications on vaccine design, challenging the dogma that MSPs are indispensable invasion engines. Although the authors only deleted bp 132-819, the data based on Western blot, IFA, and RNAâseq provide <bold>compelling</bold> evidence that while MSP2 is dispensable for growth, it serves as an immune modulator for AMA1. This work will be of particular interest to scientists working on different aspects of Plasmodium biology and vaccinology.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107603.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Henshall et al. delete the highly abundant merozoite surface protein PfMSP2 from two Plasmodium falciparum laboratory lines (3D7 and Dd2) using CRISPR-Cas9. Parasites lacking MSP2 replicate and invade red cells normally, opposing the experimental history that suggests MSP2 is essential. Unexpectedly, the knock-outs become more susceptible to several inhibitory antibodies - most strikingly those that target the apical antigen AMA1-while antibodies to other surface or secreted proteins are largely unaffected. Recombinant MSP2 added in vitro can dampen AMA1-antibody binding, supporting a &quot;conformational masking&quot; model. The reported data suggest that MSP2 helps shield key invasion ligands from host antibodies and may itself be a double-edged vaccine target.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107603.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors were trying to establish the role of Plasmodium falciparum surface protein 2 in merozoite biology, specifically the process of erythrocyte invasion.</p>
<p>Strengths:</p>
<p>The major strengths of the manuscript are in the Plasmodium falciparum genetic and phenotyping approaches. PfMSP2 knockouts are made in two different strains, which is important as it is known that invasion pathways can vary between strains, but is a level of comprehensiveness that is not always delivered in P. falciparum genetic studies. The knockout strains are characterised very thoroughly using multiple different assays, and the authors should be commended for publishing a good deal of negative data, where no phenotype was detected. This is not always done, but is very helpful for the field and reduces the potential for experimental redundancy, i.e., others repeating work that has already been performed but never published. The quality of the writing, referencing, and figures is also generally strong, although a few minor typos and technical comments on presentation have been communicated to the authors.</p>
<p>Weaknesses:</p>
<p>There are, however, some areas that are weaker.</p>
<p>(1) The section describing Laverania and avian Plasmodium MSP2 comparison is a lengthy section and could be told much more concisely for clarity in delivering the key message, i.e., that conservation in distantly related Plasmodium species could indicate an important function. The identification of MSP2-like genes in avian Plasmodium species was highlighted previously in the referenced Escalante paper, so it is not entirely novel, although this paper goes into more detailed characterisation of the extent of conservation. Overall, this section takes up much more space in the manuscript than is merited by the novelty and significance of the findings.</p>
<p>(2) Characterisation of the knockout strains is generally thorough, though relatively few interactions were followed by live microscopy (Figures 3E-H). A minimum of 30 merozoites were followed in each assay (although the precise number is not specified in the figure or legend), but there are intriguing trends in the data that could potentially have become significant if n was increased.</p>
<p>(3) The comparative RNAseq data is interesting, but is not followed up to any significant degree. Multiple transcripts are up-regulated in the absence of PfMSP2, but they are largely dismissed because they are genes of unknown function, not previously linked to invasion, or lack an obvious membrane anchor. Having gone to the lengths of exploring potentially compensatory changes in gene expression, it is disappointing not to validate or explore the hits that result.</p>
<p>(4) Given the abundance of PfMSP2 on the merozoite surface, it would have been interesting to see whether the knockout lines have any noticeable difference in surface composition, as viewed by electron microscopy, although, of course, this experiment relies on access to the appropriate facilities.</p>
<p>(5) One of the key findings is that deletion of PfMSP2 increases inhibition by some antibodies/nanobodies (some anti-CSS2, some anti-AMA1) but not others (anti-EBA/RH, anti-EBA175, anti-Rh5, anti-TRAMP, some anti-CSS2, some anti-AMA1). The data supporting these changes in inhibition are solid, but the selectivity of the effect (only a few antibodies, and generally those targeting later stages in invasion) is not really discussed in any detail. Do the authors have a hypothesis for this selectivity? The authors make attempts to explore the mechanisms for this antibody-masking (Figure 7), but the data is less solid. Surface Plasmon Resonance was non-conclusive, while an ELISA approach co-incubating MSP2 and anti-AMA1 antibodies to wells coated with AMA1 lacks appropriate controls (eg, including other merozoite proteins in similar experiments).</p>
<p>Overall, the claim that PfMSP2 is non-essential for in vitro growth is well justified and is an important contribution to the field. The impact of PfMSP2 deletion on antibody inhibition (which is highlighted in the title of the manuscript) and the mechanism behind it is much less definitive, but does open up an interesting area for further investigation, with more work to be done.</p>
</body>
</sub-article>
</article>